Page last updated: 2024-12-04

thioctic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID864
CHEMBL ID33864
CHEBI ID16494
SCHEMBL ID51065
MeSH IDM0012565

Synonyms (277)

Synonym
.alpha.-liponic acid
(rs)-.alpha.-lipoic acid
lipothion
tioctacid
dl-lipoic acid
tioctidasi
(.+-.)-lipoic acid
thioctsan
nsc-90788
(.+-.)-thioctic acid
liposan
dl-6,8-thioctic acid
(.+-.)-.alpha.-lipoic acid
dl-.alpha.-lipoic acid
dl-6-thioctic acid
thioctacid
(rs)-lipoic acid
5-(dithiolan-3-yl)valeric acid
alpha-liponsaeure
6-thiotic acid
CHEBI:16494 ,
thioctansaeure
alpha-lipoic acid
thioctate
6-thioctic acid
6,8-thiotic acid
1,2-dithiolane-3-valeric acid
5-(1,2-dithiolan-3-yl)pentanoic acid
5-[3-(1,2-dithiolanyl)]pentanoic acid
acetate-replacing factor
thioktsaeure
liponic acid
thioctsaeure
5-(1,2-dithiolan-3-yl)valeric acid
KBIO1_000912
DIVK1C_000912
NCI60_042014
smr000058198
MLS000069736
brn 0122410
tioctidasi acetate replacing factor
6,8-dithiooctanoic acid
alpha-liponsaeure [german]
pyruvate oxidation factor
einecs 200-534-6
thioktsaeure [german]
thioctic acid [jan]
thioctan
protogen a
thiotomin (tn)
thioctic acid (jan)
D00086
SPECTRUM_001618
thiooctic acid
IDI1_000912
dl-6,8-dithiooctanoic acid
SPECTRUM5_001298
BSPBIO_002835
.alpha.-lipoic acid
1,2-dithiolane-3-pentanoic acid
1077-28-7
biletan
NCGC00090872-01
(+-)-1,2-dithiolane-3-pentanoic acid
dl-1,2-dithiolane 3-valeric acid
brn 0081853
1,2-dithiolane-3-valeric acid, (+-)-
dl-1,2-dithiolane-3-valeric acid
dl-1,2-dithiolan-3-valeriansaeure [german]
1,2-dithiolane-3-pentanoic acid, (+-)-
einecs 214-071-2
thioctic acid dl-form
nsc 90788
nsc 628502
alpha-liponic acid
dl-alpha-lipoic acid
6,8-thioctic acid
LIPOIC-ACID ,
dl-thioctic acid
thioctic acid
C00725
5-(dithiolan-3-yl)pentanoic acid
nsc628502
rac-lipoate
(+/-)-1,2-dithiolane-3-pentanoic acid
nsc90788
(+/-)-alpha-lipoic acid, bioreagent, cell culture tested, >=99%
d,l-thioctic acid
alpha lipoic acid
bdbm10515
d,l-lipoic acid
lipoic acid (la)
chembl33864 ,
cid_864
NCGC00090872-03
NCGC00090872-05
NCGC00090872-02
KBIO2_004666
KBIO3_002335
KBIOSS_002098
KBIO2_002098
KBIOGR_000853
KBIO2_007234
SPECTRUM3_001188
NINDS_000912
SPBIO_001609
SPECTRUM4_000217
SPECTRUM2_001605
SPECTRUM1503941
NCGC00090872-04
pleomix alpha
biomolipon
duralipon
alpha lipogamma
thioctacide t
espa-lipon
alpha-lipogamma
alphalipogamma
biomo lipon
espa lipon
alpha-lipon stada
liponsaure-ratiopharm
liponsaureratiopharm
alphalipon stada
verla lipon
alpha liponsaure von ct
alpha lippon al
alpha lipon stada
MLS001332379
MLS002153365
MLS001332380
(+/-)-alpha-lipoic acid, >=98.0%
(+/-)-alpha-lipoic acid, synthetic, >=99% (titration), powder
acidum thiocticum
thiocacid
lipoic acid, dl-
lipoic acid, alpha
a-lipoicum acidum
nsc-628502
BMSE000542
()-1,2-dithiolane-3-pentanoic acid
1,2-dithiolane-3-pentanoic acid, (.+-.)-
1,2-dithiolane-3-valeric acid, (.+-.)-
()-alpha-lipoic acid
1,2-dithiolane-3-pentanoic acid, (+-)- (9ci)
HMS502N14
5-[1,2]dithiolan-3-yl-pentanoic acid
L0058
HMS1922M22
STK801969
NCGC00016032-06
AKOS000121582
BBL013878
A801751
alpha-lipon 300
(+-)-thioctic acid
(+-)-alpha-lipoic acid
dl-1,2-dithiolan-3-valeriansaeure
lipoic acid, alpha [nf]
thiotacid
thioctic acid [inn:ban:jan]
alipure
unii-73y7p0k73y
5-19-07-00237 (beilstein handbook reference)
(+-)-lipoic acid
(rs)-alpha-lipoic acid
hsdb 7818
73y7p0k73y ,
tox21_303092
dtxcid705508
NCGC00256970-01
cas-1077-28-7
dtxsid7025508 ,
NCGC00259357-01
tox21_201808
pharmakon1600-01503941
nsc-758651
nsc758651
tox21_110285
S3996
CCG-39063
NCGC00016032-04
NCGC00016032-05
NCGC00016032-02
NCGC00016032-03
NCGC00016032-09
NCGC00016032-07
NCGC00016032-08
FT-0670812
(+/-)-a-lipoic acid
FT-0625429
FT-0622068
AB09328
EPITOPE ID:150922
dl-thiocticacid
AKOS016339634
alpha lipoic acid [usp impurity]
thioctic acid [mi]
alpha-lipoic acid [vandf]
.delta.-(3-(1,2-dithiacyclopentyl))pentanoic acid
thioctic acid dl-form [mi]
5-((3rs)-1,2-dithiolan-3-yl)pentanoic acid
thioctic acid [ep monograph]
AM84329
thioctic acid [inci]
thioctic acid [who-dd]
thioctic acid [hsdb]
.alpha.-lipoic acid, (+/-)-
thioctic acid [mart.]
alpha lipoic acid [vandf]
a-lipoicum acidum [hpus]
thioctic acid, (+/-)-
5-(3-(1,2-dithiolanyl))pentanoic acid
alpha lipoic acid [usp-rs]
SCHEMBL51065
a-lipoic acid
tox21_110285_1
NCGC00016032-11
KS-1322
CS-4370
thioctic acid, dl-form
(.+/-.)-lipoic acid
dl-1,2-dithiolane-3-pentanoic acid
5-(1,2-dithiolan-3-yl)pentanoic acid #
1,2-dithiolane-3-valeric acid, (.+/-.)-
1,2-dithiolane-3-pentanoic acid, (.+/-.)-
alphalipoic-acid
AC-22673
HY-N0492
HMS3649H08
AB00052393_09
lip(s2)
mfcd00005474
(r)-(+)-alpha-lipoic acid;r-(+)-thioctic acid
J-520421
J-002007
F2191-0208
afae'a centa' nota inverted exclamation markafasa'a|afae'adaggeratrade mark?-lipoic acid
dl-a-lipoic acid
( inverted exclamation marka)-a-lipoic acid
sr-01000737460
SR-01000737460-2
alpha lipoic acid, united states pharmacopeia (usp) reference standard
thioctic acid, european pharmacopoeia (ep) reference standard
thioctic acid for system suitability, european pharmacopoeia (ep) reference standard
thioctic acid containing impurity b, european pharmacopoeia (ep) reference standard
thioctic acid (alpha-lipoic acid)
SBI-0051871.P002
SY010902
FT-0670813
(r)-(+)-(c) paragraph sign-lipoic acid
(r)-(+)-1,2-dithiolane-3-pentanoic acid; r-(+)-thioctic acid; r-(+)-alpha-lipoic acid
BCP18944
(rs)-thioctic acid
Q312229
Z56969297
SR-01000737460-6
thioctic acid;1,2-dithiolane-3-pentanoic acid;5-(1,2-dithiolan-3-yl)valeric acid
BCP13221
BCP14048
EN300-17612
alpha-lipoic-acid
(+/-)?-?1,2-?dithiolane-?3-?pentanoic acid
5-(1,2)dithiolan-3-yl-pentanoic acid
(+/-)-?-lipoic acid
HMS3885I16
AC7875
BP-31070
alpha -lipoic acid
NCGC00016032-14
r)-(+)-|a-lipoic acid ooethyaoethaea
r-(+)-alpalipoic acid
(s)-(-)-thiocticacid
SB49517
rac ?-lipoic acid
HY-N0492R
CS-0694773

Research Excerpts

Overview

Thioctic acid is a naturally occurring antioxidant existing in two optical isomers (+)- and (-)-thioctic Acid and in the racemic form.

ExcerptReferenceRelevance
"Thioctic acid is a naturally occurring antioxidant existing in two optical isomers (+)- and (-)-thioctic acid and in the racemic form."( Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury.
Amenta, F; Di Cesare Mannelli, L; Ghelardini, C; Nwankwo, IE; Pacini, A; Tayebati, SK; Tomassoni, D, 2013
)
1.41

Effects

Thioctic acid (TA) has favourable effects on glucose metabolism. The influence of this drug at two different doses was investigated in the heart after 2 weeks of diabetes.

ExcerptReferenceRelevance
"As thioctic acid (TA) has favourable effects on glucose metabolism, the influence of this drug at two different doses (0.1 mg/ml and 0.5 mg/ml, added to the perfusion medium) was investigated in the heart after 2 weeks of diabetes, using the working rat heart model at physiological workload about 45 min."( The influence of thioctic acid on metabolism and function of the diabetic heart.
Bretzel, RG; Federlin, K; Lehmann, E; Lehmann, U; Strödter, D; Tritschler, HJ, 1995
)
1.14
"Thioctic acid also has been found to elevate the level of glutathione and reactive oxidants, and increase CD4 and CD8 levels in PWAs."( Thioctic acid.
,
)
2.3

Treatment

Thioctic acid treatment also enhanced recovery after partial denervation of muscles in both normal and acrylamide-poisoned animals. Pretreatment with thioctic Acid has no negative influence on the chemotherapeutic efficacy of cyclophosphamide against i.p.

ExcerptReferenceRelevance
"Thioctic acid treatment was discontinued 2 days after admission."( Thioctic acid-induced acute cholestatic hepatitis.
Castiglioni, T; Ridruejo, E; Silva, MO, 2011
)
2.53
"Also thioctic acid treatment did not reverse the BSO induced depletion of GSH or prevent the potentiation of 6-OHDA neurotoxicity produced by BSO."( Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain.
Jenner, P; Marsden, CD; Seaton, TA, 1996
)
2.19
"Thioctic acid treatment did not improve cognitive function."( A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
, 1998
)
1.26
"Thioctic acid treatment also enhanced recovery after partial denervation of muscles in both normal and acrylamide-poisoned animals."( The effects of thioctic acid on motor nerve terminals in acrylamide-poisoned rats.
Kemplay, S; Martin, P; Wilson, S,
)
1.21
"Pretreatment with thioctic acid has no negative influence on the chemotherapeutic efficacy of cyclophosphamide against i.p. "( [Effect of thioctic acid (alpha-limpoic acid) on the chemotherapeutic efficacy of cyclophosphamide and vincristine sulfate].
Berger, M; Habs, M; Schmähl, D, 1983
)
0.99
"Treatment with thioctic acid did not alter the heart rate response to standing up or Valsalva manoeuvre of the diabetics with peripheral neuropathy."( [Diabetic autonomic neuropathy of the heart and its treatment with thioctic acid].
Heuer, LJ; Studt, J, 1984
)
0.84
"treatment with thioctic acid resulted in a distinct improvement of subjective complaints."( Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy.
Sachse, G; Willms, B, 1980
)
0.98

Toxicity

ExcerptReferenceRelevance
" L-HCA induced a concentration-dependent neurotoxic effect, estimated by cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction, in primary neurons, but was significantly more toxic for hippocampal (EC(50)=197 microM) compared with cortical neurons (EC(50)=1016 microM) whereas D-HCA demonstrated only moderate (<20%) toxicity."( Inhibition of L-homocysteic acid and buthionine sulphoximine-mediated neurotoxicity in rat embryonic neuronal cultures with alpha-lipoic acid enantiomers.
Cuisinier, C; Jones, C; Lestage, P; Lockhart, B; Peyroulan, D; Villain, N, 2000
)
0.31
"Vitamin C (ascorbate) is toxic to tumour cells, and has been suggested as an adjuvant cancer treatment."( Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours.
Casciari, JJ; Jackson, JA; Meng, XL; Riordan, HD; Riordan, NH; Schmidt, TL, 2001
)
0.31
"Mercury exposure is the second-most common cause of toxic metal poisoning."( Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity.
Patrick, L, 2002
)
0.31
"Adriamycin, which is widely used in the treatment of various neoplastic conditions, exerts toxic effects in several organs."( The influence of lipoic acid on adriamycin induced nephrotoxicity in rats.
Balachandar, AV; Malarkodi, KP; Varalakshmi, P, 2003
)
0.32
"The objective of the present work was to evaluate the toxic effects of sodium arsenite, As(III), in mice and the protective effect of 2 antioxidants, hesperidin and lipoic acid, against the observed As(III)-induced toxicity."( Protective activity of hesperidin and lipoic acid against sodium arsenite acute toxicity in mice.
Carvalho, F; Carvalho, M; das Neves, RN; de Bastos, ML; de Pereira, ML; Fernandes, E; Soares, E,
)
0.13
" Prevention of the acute adverse effects of doxorubicin on myocardium may hinder the later development of cardiomyopathy."( Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound.
Czopf, L; Deres, P; Habon, T; Halmosi, R; Hideg, K; Kalai, T; Kovacs, K; Palfi, A; Sumegi, B; Toth, A; Toth, K, 2005
)
0.33
" We investigated the toxic effects of excess extracellular copper on motor neuronal cells expressing human mutant SOD1 (G93A), and evaluated the neuroprotective effects of energy metabolism intermediates or cofactors."( Pyruvate protects motor neurons expressing mutant superoxide dismutase 1 against copper toxicity.
Kim, HJ; Kim, JM; Kim, M; Lee, KW; Park, JH; Sung, JJ, 2005
)
0.33
" Arsenic as an environmental agent is considered to be a toxic substance due to its carcinogenic potential in humans."( Combined efficacies of DL-alpha-lipoic acid and meso 2,3 dimercaptosuccinic acid against arsenic induced toxicity in antioxidant systems of rats.
Devi, MA; Kokilavani, V; Panneerselvam, C; Sivarajan, K, 2005
)
0.33
" ALA was not acutely toxic to rats (LD(50)>2000mg/kg bw, OECD method 425)."( Safety evaluation of alpha-lipoic acid (ALA).
Cremer, DR; Lynch, B; Rabeler, R; Roberts, A, 2006
)
0.33
" GSH plays a key role in antioxidant defense, and HNE exposure causes an initial depletion of GSH that leads to gradual toxic accumulation of reactive oxygen species."( Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
Abdul, HM; Butterfield, DA, 2007
)
0.34
" Moreover, we examined a potential renal toxic mechanism(s) of arsenic trioxide by using a toxicity-related gene and investigated potential treatments to reduce the renal toxicity of arsenic trioxide."( An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide.
Fujimura, A; Oshima, Y; Sasaki, A, 2007
)
0.34
" Both parenteral and up to a 2-year time period of oral supplementation of ALA appears to be safe without affecting glycemic control."( Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy.
Foster, TS,
)
0.13
"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection."( Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
Camozzi, F; Lauria, G; Melli, G; Podini, P; Quattrini, A; Taiana, M; Taroni, F; Triolo, D, 2008
)
0.35
"In the present investigation, we have used adenosine triphosphatase (ATPase) activity as biochemical test of toxic action of lindane that was explained by lipid peroxidation model."( Inhibition of lindane-induced toxicity using alpha-lipoic acid and vitamin E in the brain of Mus musculus.
Bhatt, DK; Bist, R; Misra, S, 2010
)
0.36
" The incidence rates of adverse effects were 25."( [Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy].
Chen, L; Gu, XM; Li, H; Liu, C; Lu, ZQ; Ning, G; Tang, ZY; Wu, JC; Zhang, SS, 2010
)
0.36
"The clinical use of arsenic trioxide (ATO) is often limited because of its adverse effects."( Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Ando, H; Fujimura, A; Hosohata, K; Koshimizu, TA; Kumazaki, M; Oshima, Y; Sasaki, A; Ushijima, K, 2011
)
0.37
" The rates of serious adverse events were higher on ALA (38."( Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Boulton, AJ; Dyck, PJ; Freeman, R; Litchy, WJ; Low, PA; Maus, J; Munzel, U; Samigullin, R; Schütte, K; Tritschler, H; Vinik, AI; Ziegler, D, 2011
)
0.37
" Combination of α-lipoic acid efficiently halting deleterious toxic effects of L-dopa, revealed normalization of catalepsy score in addition to amelioration of neurochemical parameters and apparent preservation of striatal ultrastructure integrity, indicating benefit of both symptomatic and neuroprotective therapy."( Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Abdin, AA; Sarhan, NI, 2011
)
0.37
" The treatment with lipoic acid and glutathione reduced the toxic effects of these metals in all cases."( Monitoring the toxic effects of Pb, Cd and Cu on hematological parameters of Wistar rats and potential protective role of lipoic acid and glutathione.
Cvetković, TP; Jovanović, J; Kocić, G; Krstić, N; Nikolić, R; Radosavljević-Stevanović, N, 2015
)
0.42
" However, its use is limited due to its serious side effect on kidneys."( Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity.
El-Desoky, KI; El-Sisi, Ael-D; El-Syaad, ME; Moussa, EA, 2015
)
0.42
"This study evaluates the toxic effects of chrysene (a component from cigarette smoke) on Müller cells (MIO-M1) in vitro and investigates whether the inhibitor lipoic acid can reverse the chrysene-induced toxic effects."( Protective effects of lipoic acid on chrysene-induced toxicity on Müller cells in vitro.
Gupta, N; Kenney, MC; Kuppermann, BD; Limb, GA; Luczy-Bachman, G; Mansoor, S, 2013
)
0.39
" The toxic effects of IFOS were analyzed by oxidative parameters and caspase 3 immunohistochemical examinations of brain tissue."( Effect of alpha lipoic acid on ifosfamide-induced central neurotoxicity in rats.
Albayrak, A; Bilen, S; Fadillioglu, E; Ginis, Z; Kurt, SN; Ozturk, G, 2014
)
0.4
"8) suggesting that the camptothecin regimen was synergistic and that the addition of sodium-R-alpha lipoate was important for reducing the camptothecin dose and potential for adverse effects."( Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells.
Gao, D; Ibrahim, S; Sinko, PJ, 2014
)
0.4
" No serious adverse events were reported in a placebo-controlled, sequential dose escalation Phase 1 clinical trial."( Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury.
Beeuwkes, R; Casale, R; Kates, SA; Lader, AS, 2014
)
0.4
"1 nm) for 24 hours pretreatment with or without methyltransferase inhibitor 5-aza-2'-deoxycytidine and the reactive oxygen species (ROS) scavenger α-lipoic acid to assess the possible role of methylation and ROS in the toxic effect of TNPs."( Cross talk between poly(ADP-ribose) polymerase 1 methylation and oxidative stress involved in the toxic effect of anatase titanium dioxide nanoparticles.
Bai, W; Chen, Y; Gao, A, 2015
)
0.42
" Our findings demonstrate that SO and (or) ALA supplementation can alleviate the toxic effects of DZN via their potent antioxidant and free radical-scavenging activities."( Synergistic ameliorative effects of sesame oil and alpha-lipoic acid against subacute diazinon toxicity in rats: hematological, biochemical, and antioxidant studies.
Abdel-Daim, MM; El-Sayed, YS; Ghazy, EW; Taha, R, 2016
)
0.43
" The outcomes measured were as follows: clinical efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV, peroneal SNCV and adverse effects."( Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy.
Jiang, DQ; Li, MX; Ma, YJ; Wang, Y, 2016
)
0.43
" Used as dietary supplement alpha-lipoic acid was demonstrated to be safe for living organisms even when administered at high doses."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46
" Maternal safety was assessed by monitoring for adverse reactions, physical and clinical examination, including a morbidity assessment."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46
" No adverse effect was noticed in mothers or newborns."( Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study.
Colannino, G; Monastra, G; Parente, E; Picconi, O, 2017
)
0.46
" P-glycoprotein (P-gp) is a well-known ATP-binding cassette (ABC) transporter that plays a crucial role in the extrusion of toxic substances, decreasing their accumulation and potential intracellular effects in virtue of its broad substrate specificity, its expression in many excretory tissues and its large efflux capacity."( Cytoprotection of lipoic acid against toxicity induced by saxitoxin in hippocampal cell line HT-22 through in silico modeling and in vitro assays.
Cornetet, LR; de Souza Votto, AP; Dos Santos Machado, K; Durruthy, MG; Fagan, SB; Gama, S; Monserrat, JM; Portantiolo, A; Ramos, P; Schmitz, M; Tonel, MZ; Werhli, A; Yunes, JS, 2018
)
0.48
" Stimulation of spermatogenesis using the antioxidant complex SpermActin Forte is an effective and safe method of treating male infertility."( [Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility].
Gamidov, SI; Ovchinnikov, RI; Popova, AY, 2019
)
0.51
" Having determined the effective concentrations of LPS (1 mg/mL) that could reduce blastocyst formation rate by around 50% and the optimal concentration of ALA (10 μM) that could attenuate the toxic effects of LPS on blastocyst formation, the following indices were defined: inner cell mass and trophectoderm cell numbers, blastocyst mitochondrial distribution, ROS and GSH levels, as well as the relative expression of Tlr-4."( The attenuation of the toxic effects of LPS on mouse pre-implantation development by alpha-lipoic acid.
Hajian, M; Kowsar, R; Mahdavi, AH; Mokhtari, S; Nasr-Esfahani, MH; Varnosfaderani, SR, 2020
)
0.56
" Based on our findings, DEHP significantly reduced the production and count of sperms; these toxic effects were associated with alterations in the serum hormone levels."( Protective effect of alpha-lipoic acid on di-(2-ethylhexyl) phthalate-induced testicular toxicity in mice.
Goudarzi, M; Haghi Karamallah, M; Kalantar, H; Kalantar, M; Malayeri, A; Mansouri, E, 2020
)
0.56
" These CoNPs can be first accumulated around the implant to cause adverse local reactions and then enter into the blood vessels followed by reaching the liver, heart, brain, kidney, and other organs through systematic circulation, which leads to multi-system toxicity symptoms."( Alpha lipoic acid antagonizes cytotoxicity of cobalt nanoparticles by inhibiting ferroptosis-like cell death.
Gu, JH; Liu, F; Liu, Y; Ni, D; Sun, H; Zhang, W; Zhou, Z; Zhu, W, 2020
)
0.56
" However, nephrotoxicity is considered to be a critical adverse effect that limits CMS's clinical use."( Alpha-lipoic acid alleviates colistin nephrotoxicity in rats.
Arslan, S; Bilici, G; Cavdar, C; Cavdar, Z; Heybeli, C; Kocak, A; Oktan, MA; Ozbal, S; Ural, C; Yilmaz, O, 2021
)
0.62
"To evaluate the safety of four different dosages of alpha lipoic acid (400, 600, 800, and 1200 mg) as food supplement on adverse events related to alpha lipoic acid consumption and efficacy on glycemic status and lipid profile in subjects with euglycemia or dysglycemia."( Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention.
D'Angelo, A; Derosa, G; Maffioli, P; Preti, P, 2020
)
0.56
" Adverse events of patients during alpha lipoic acid treatment included nausea, vomiting, dizziness, cutaneous rash, hypoglycemia, and hypotension."( Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention.
D'Angelo, A; Derosa, G; Maffioli, P; Preti, P, 2020
)
0.56
" Clinical assessments, including DCNVA and adverse events (AEs), were recorded at each study visit."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.62
"UNR844 administration (n = 50) produced no safety concerns and was well-tolerated, with no clinically-relevant changes in best-corrected distance visual acuity, pupil size, intraocular pressure, or discontinuations due to adverse events."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.62
"Although many studies have reported toxic effects of cadmium (Cd) and lead (Pb) in the central nervous system, few studies have investigated the combined toxicity of Cd and Pb."( Alpha-Lipoic Acid Attenuates Cadmium- and Lead-Induced Neurotoxicity by Inhibiting Both Endoplasmic-Reticulum Stress and Activation of Fas/FasL and Mitochondrial Apoptotic Pathways in Rat Cerebral Cortex.
Bian, JC; Gu, JH; Liu, XZ; Liu, ZP; Wang, L; Wen, SQ; Yuan, Y; Zhao, SW; Zhu, QP; Zou, H, 2021
)
0.62
" Participants underwent two visits (at baseline = t0, and after 2 months = t1) in which two validated questionaries for pain (numerical rating scale [NRS] and visual analogue scale [VAS]) were collected; fasting blood glucose assessment, adverse effects, and renal and hepatic toxicity were also monitored."( Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial.
Dacrema, M; Daglia, M; Di Minno, A; Esposito, C; Piccinocchi, G; Piccinocchi, R; Sacchi, R; Santarcangelo, C; Ugo Garzarella, E, 2021
)
0.62
"At t1, none of subjects treated with ALA reported a decreased glycemia or adverse effects."( Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial.
Dacrema, M; Daglia, M; Di Minno, A; Esposito, C; Piccinocchi, G; Piccinocchi, R; Sacchi, R; Santarcangelo, C; Ugo Garzarella, E, 2021
)
0.62
" Although it is a safe oral molecule, there have been eight cases of ALA toxicity reported."( Alpha Lipoic Acid Toxicity: The First Reported Mortality in an Adult Patient After Multiorgan Failure.
Abu-Alfa, A; Al Balushi, H; El Helou, C; El Zahran, T; Gittinger, M; Halabi, Z; Kaakour, A; Steck, AR, 2023
)
0.91
"Nutraceuticals like alpha-lipoic acid (ALA) may have potential benefits as prophylactic agents for adolescent migraine, with fewer adverse events than existing medications."( Evaluation of Safety and Efficacy of Add-on Alpha-Lipoic Acid on Migraine Prophylaxis in an Adolescent Population: A Randomized Controlled Trial.
Jena, M; Maiti, R; Mishra, BR; Puliappadamb, HM; Satpathy, AK, 2023
)
0.91
" This study was planned to determine whether ALA might protect Nile tilapia's kidneys from the toxic effects of GA and the probable underlying mechanisms."( Alpha-lipoic acid suppresses gibberellic acid nephrotoxicity in Nile tilapia (Oreochromis niloticus) via modulating oxidative stress, inflammation, cytokine production, and apoptosis.
Abd-Elhakim, YM; Abdel-Warith, AA; Arisha, AH; Davies, SJ; El-Houseiny, W; Hassan, BA; Metwally, MMM; Younis, EM, 2023
)
0.91

Pharmacokinetics

In this study, the pharmacokinetic interaction between pregabalin and thioctic acid was investigated at steady state. The study involved 16 patients (8 with severely reduced renal function, 8 with end-stage renal disease needing hemodialysis)

ExcerptReferenceRelevance
"The features of the pharmacokinetics of preparations of alpha-lipoic acid (lipoic acid, thioctacide) as compared with their pharmacodynamic effects were studied in 125 patients with chronic diffuse diseases of the liver of viral and alcohol etiology."( [Pharmacokinetics of preparations of lipoic acid and their effect on ATP synthesis, processes of microsomal and cytosol oxidation in hepatocytes in liver damage in man].
Bendikov, EA; Loginov, AS; Nilova, TV; Petrakov, AV,
)
0.13
" The synthesis and the physicochemical and pharmacokinetic evaluation of a CDS modeling the lipoyl and other ester derivatives of chlorambucil (an antineoplastic agent) and cromolyn (a bischromone used in antiasthma prophylaxis) as compared with their respective parent drugs are described."( Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue.
Bodor, N; Eberst, K; Marvanyos, E; Saah, M; Wu, WM, 1996
)
0.29
"For the pharmacokinetic study, a single, 600-mg dose of either controlled-release LA (CRLA) or quick-release LA (QRLA) was administered orally to 12 normal human subjects."( Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.
Evans, JL; Gavin, LA; Goldfine, ID; Heymann, CJ,
)
0.13
"In an open-label, parallel-group study involving 16 patients (8 with severely reduced renal function, 8 with end-stage renal disease needing hemodialysis), the effect of renal function on the pharmacokinetics, metabolism, and safety and of alpha-lipoic acid (thioctic acid) was evaluated by comparing the pharmacokinetic parameters with those of a reference group of 8 healthy subjects."( Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Achenbach, H; Hermann, R; Preiss, C; Preiss, R; Ruus, P; Teichert, J; Tuemmers, T, 2005
)
0.51
"As anticipated from the preliminary study, NaRLA is less prone to polymerization, completely soluble in water, and displays significantly higher Cmax and AUC values and decreased time to maximum concentration (Tmax) and T1/2 values than RLA or rac-LA."( The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects.
Carlson, DA; Fischer, SJ; Packer, L; Smith, AR; Young, KL, 2007
)
0.34
" We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200 mg lipoic acid."( Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.
Alvarez, L; Bourdette, DN; Cherala, G; Koop, DR; Marracci, GH; Munar, MY; Shinto, L; Stuber, LE; Yadav, V, 2010
)
0.36
" Noncompartmental analysis was used to determine pharmacokinetic parameters of DL-α-lipoic acid."( Pharmacokinetics of orally administered DL-α-lipoic acid in dogs.
Avila, A; Gross, KL; Joshi, DK; Zicker, SC, 2010
)
0.36
" Other significant changes in pharmacokinetic parameters were variable and dependent on dosage and method of delivery."( Pharmacokinetics of orally administered DL-α-lipoic acid in dogs.
Avila, A; Gross, KL; Joshi, DK; Zicker, SC, 2010
)
0.36
"Values for pharmacokinetic parameters of orally administered DL-α-lipoic acid may differ significantly when there are changes in dosage, method of administration, and fed status."( Pharmacokinetics of orally administered DL-α-lipoic acid in dogs.
Avila, A; Gross, KL; Joshi, DK; Zicker, SC, 2010
)
0.36
" The half-life and MRT values further show that new formulation is absorbed consistently and rapidly and is eliminated efficiently."( Single dose bioavailability and pharmacokinetic study of a innovative formulation of α-lipoic acid (ALA600) in healthy volunteers.
Capacchietti, M; Fasani, R; Ferrari, P; Mignini, F; Napolioni, V; Reggiardo, G, 2011
)
0.37
"ALA600 formulation is characterized by rapid absorption, high bioavailability, brief half-life and low toxicity."( Single dose bioavailability and pharmacokinetic study of a innovative formulation of α-lipoic acid (ALA600) in healthy volunteers.
Capacchietti, M; Fasani, R; Ferrari, P; Mignini, F; Napolioni, V; Reggiardo, G, 2011
)
0.37
" The utility of the assay was confirmed by pharmacokinetic study of N2L in rats."( Determination of newly synthesized lipoic acid-niacin dimer in rat plasma by UPLC/electrospray ionization tandem mass spectrometry: assay development, validation and application to a pharmacokinetic study.
Chen, X; Gao, J; Huang, P; Jiang, Y; Pi, R; Xie, Y; Yao, M; Zhu, S, 2014
)
0.4
"Despite its numerous potentials, oral administration of α-lipoic acid (ALA) is characterised by pharmacokinetic limitations that reduce its therapeutic efficacy."( (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy.
Brufani, M; Figliola, R, 2014
)
0.4
" However, after intravenous administration of the racemic mixture, the pharmacokinetic profiles, initial concentration (C₀), AUC, and half-life (T1/2) of the enantiomers were not significantly different."( Enantioselective Pharmacokinetics of α-Lipoic Acid in Rats.
Hirota, T; Ikuta, N; Okamoto, H; Terao, K; Uchida, R, 2015
)
0.42
" In this study, the pharmacokinetic interaction between pregabalin and thioctic acid was investigated at steady state."( Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers.
Ahn, LY; Lee, H; Lim, KS; Rhee, SJ; Yu, KS, 2018
)
0.94
" Pharmacokinetic parameters were calculated by using noncompartmental analysis methods."( Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers.
Ahn, LY; Lee, H; Lim, KS; Rhee, SJ; Yu, KS, 2018
)
0.71
" A single dose clinical pharmacokinetic study was carried out for the selected formulation."( Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil.
Ahmed, OAA, 2018
)
0.48
" The pharmacokinetic parameters for ALA/HCO/SCP and ALA bulk powder gave similar values but were significantly different from those of MC-50F."( Characterization and pharmacokinetic evaluation of microcomposite particles of alpha lipoic acid/hydrogenated colza oil obtained in supercritical carbon dioxide.
Aida, TM; Harada, T; Higuchi, S; Honjo, M; Irie, K; Kato, T; Mishima, K; Misumi, M; Orii, H; Sano, K; Satho, T; Sharmin, T; Suetsugu, T; Yamada, M; Yasuhide, O, 2020
)
0.56
" As the radiolabeling strategy can significantly impact pharmacokinetics and biodistribution, we explored in this work a site-specific radiofluorination strategy on an anti-PD-L1 fragment antigen-binding (Fab) and compared the pharmacokinetic and biodistribution properties with the same Fab labeled using stochastic radiolabeling chemistry."( Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand.
Bouleau, A; Chevaleyre, C; Dubois, S; Evans, MJ; Kereselidze, D; Kuhnast, B; Nozach, H; Richard, M; Specklin, S; Tran, VL; Truillet, C, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" coli administration showed a decline in the thiol content of the cell accompanied by high malondialdehyde levels along with lowered activities of catalase, superoxide dismutase and glutathione peroxidase with an added effect observed when gentamicin was administered along with it."( Evaluation of the effect of lipoic acid administered along with gentamicin in rats rendered bacteremic.
Malarkodi, KP; Sandhya, S; Varalakshmi, P, 2003
)
0.32
"To investigate the potential drug-drug interaction (DDI) between lipoic acid (LA) and valproate (VA) via the mitochondrial beta-oxidation pathway in rats."( Investigation of the drug-drug interaction between alpha-lipoic acid and valproate via mitochondrial beta-oxidation.
Browne, ER; Chan, EC; Goh, CW; Neo, AH; New, LS; Phua, LC, 2008
)
0.35
" The effect is increased significantly, especially in the sensory sphere (tactile, temperature and pain sensitivity), when the drug is used in combination with curantyl in dosage 50 mg twice daily for 3 months."( [The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy].
Al-Zamil, MKh, 2008
)
0.35
" In conclusion, mGST in combination with GSH has a synergistic effect in reducing airway inflammation compared to the individual antioxidants and has potential for the treatment of asthma."( Mutated glutathione S-transferase in combination with reduced glutathione shows a synergistic effect in ameliorating oxidative stress and airway inflammation.
Arora, N; Nair, S; Singh, BP; Tripathi, P, 2010
)
0.36
" We have developed a screening method to assess the best drug combination for cancer treatment based on targeting several factors implicated in tumor specific metabolism."( Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
Abolhassani, M; Baronzio, G; Bonte, J; Campion, F; Fichtner, I; Fiorentini, G; Guais, A; Israël, M; Sanders, E; Schwartz, L, 2012
)
0.38
" The effect of EGCG combined with ALA is greater than the effect of EGCG alone in all anti-inflammation and anti-oxidant experiments."( Epigallocatechin-3-gallate combined with alpha lipoic acid attenuates high glucose-induced receptor for advanced glycation end products (RAGE) expression in human embryonic kidney cells.
Jian, JH; Leu, JG; Liang, YJ; Lin, CY; Shih, CY,
)
0.13
"To evaluate the effect of alpha-lipoic acid (LA) combined with transient intensive insulin therapy on adipokine level in patients with type 2 diabetic perineuropathy (DPN)."( [Effect of alpha-lipoic acid combined with transient intensive insulin therapy on adipokine level in patients with type 2 diabetic perineuropathy].
Song, MQ; Yang, L; Zang, SF, 2013
)
0.39
" A randomized controlled trial was conducted to investigate whether CSII in combination with rosiglitazone, metformin, or α-lipoic acid separately brings about extra benefits."( Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G, 2013
)
0.39
"One hundred sixty patients with newly diagnosed type 2 diabetes were randomized to one of four treatment groups: CSII alone, CSII in combination with rosiglitazone or metformin for 3 months, or CSII with α-lipoic acid intravenous infusion for 2 weeks."( Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G, 2013
)
0.39
"The near-normoglycemia rate at the third month in CSII alone and that in combination with rosiglitazone, metformin, or α-lipoic acid was 72."( Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G, 2013
)
0.39
"Short-term CSII in combination with rosiglitazone or metformin is superior to CSII alone, yet the efficacy of the two differs in some way, whereas that with α-lipoic acid might not have an additive effect."( Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G, 2013
)
0.39
" This ligand design is combined with a novel photoligation strategy to promote the transfer of QDs to polar and buffer media."( Photoligation combined with zwitterion-modified lipoic acid ligands provides compact and biocompatible quantum dots.
Grise, H; Mattoussi, H; Palui, G; Zhan, N, 2014
)
0.4
"5 improved most of the parameters evaluated in this study without causing motor impairment demonstrating, thus, that possibly when combined with ALA a lower dose of CLZ is required."( Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
de Lucena, DF; de Sousa, CN; Gama, CS; Lima, LL; Macêdo, D; Oliveira, Tde Q; Vasconcelos, GS; Vasconcelos, SM; Ximenes, NC, 2015
)
0.42
" Lipoic acid alone or combined with paclitaxel can inhibit NF-κB expression and inhibit breast cancer cell proliferation."( Effect of lipoic acid combined with paclitaxel on breast cancer cells.
Gong, Y; Hao, XY; Li, BJ; Ren, GH, 2015
)
0.42
"We investigated the clinical value of alprostadil combined with the α-lipoic acid in treating type 2 diabetes mellitus with erectile dysfunction (DMED)."( Study on the clinical value of alprostadil combined with α-lipoic acid in treatment of type 2 diabetes mellitus patients with erectile dysfunction.
Huang, FC; Huang, Q; Li, JR; Liu, C; Zhang, HY; Zhang, L, 2016
)
0.43
"Alprostadil combined with α-lipoic acid can improve DMED patients' vascular endothelial function and erection hardness to treat erectile dysfunction with less adverse effects and better safety."( Study on the clinical value of alprostadil combined with α-lipoic acid in treatment of type 2 diabetes mellitus patients with erectile dysfunction.
Huang, FC; Huang, Q; Li, JR; Liu, C; Zhang, HY; Zhang, L, 2016
)
0.43
" The present study aimed to investigate the effects of the typical antipsychotic chlorpromazine (CP) alone or combined with the natural antioxidant alpha-lipoic acid (ALA) on changes in the hippocampal average spectral power induced by ketamine (KET)."( Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.
Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017
)
0.46
" This study aimed to investigate the effects of mirtazapine (MIRT) alone and combined with alpha-lipoic acid (ALA) against corticosterone (CORT) induced behavioral and oxidative alterations."( Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone.
de Oliveira, AA; de Sousa, CNS; de Sousa, LC; Honório Júnior, JER; Macedo, D; Maes, M; Medeiros, IDS; Oliveira, TQ; Patrocínio, CFV; Vasconcelos, GS; Vasconcelos, SMM, 2017
)
0.46
"Objective To compare the clinical effectiveness of lipoic acid combined with epalrestat versus lipoic acid in treating diabetic peripheral neuropathy(DPN)."( Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis.
Lin, HX; Lu, YK; Wang, XT; Xu, SA, 2017
)
0.46
" Epalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
"This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS, and safety of ALA combined with epalrestat for patients with DPN, compare with epalrestat alone."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
"Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
"To investigate the effect of alpha-lipoic acid (α-LA) combined with tamoxifen citrate (TC) in the treatment of oligoasthenospermia."( [Efficacy of alpha-lipoic acid combined with tamoxifen citrate in the treatment of oligoasthenospermia].
Chang, XL; Li, JD; Li, W; Teng, ZH; Wang, YX; Yang, SW; Zhang, H; Zhang, YP, 2017
)
0.46
"Alpha-lipoic acid combined with tamoxifen citrate can evidently improve semen parameters in oligoasthenospermia patients by relieving oxidative stress injury."( [Efficacy of alpha-lipoic acid combined with tamoxifen citrate in the treatment of oligoasthenospermia].
Chang, XL; Li, JD; Li, W; Teng, ZH; Wang, YX; Yang, SW; Zhang, H; Zhang, YP, 2017
)
0.46
"The aim of this study was to compare curative effects of valsartan alone or combined with alpha-lipoic acid (ALA) on inflammatory cytokine indices including hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α) and renal function indices including urinary albumin excretion rate (UAER), β2-microglobulin (β2-MG) and cystatin C (Cys C) of patients with early-stage diabetic kidney disease (DKD)."( Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease.
Jiang, Z; Li, X; Meng, F; Tan, Z, 2019
)
0.51
" However, there is a lack of evidence-based medical evidence for alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy, and this article aims to understand the clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath by a meta-analysis of published randomized controlled trials."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
0.56
" Retrieving a randomized controlled study of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath, while the language of the literature is restricted and it only includes Chinese and English literature."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
0.56
"This study will draw reliable evidence-based medical evidence for alprostadil combined with Alpha lipoic acid in the treatment of diabetic peripheral neuropathy, thus providing help for the clinical treatment of diabetic peripheral neuropathy."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
0.56
" The purpose of this study was to evaluate the efficacy of valsartan combined with α-lipoic acid on renal function in patients with DN."( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Cai, J; Jiang, D; Sun, F, 2021
)
0.62
" Randomized controlled trials (RCTs) evaluating the effects of valsartan combined with α-lipoic acid in DN patients were included."( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Cai, J; Jiang, D; Sun, F, 2021
)
0.62
" The pooled analysis indicated that α-lipoic acid combined with valsartan could remarkably reduce UAER (P < 0."( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Cai, J; Jiang, D; Sun, F, 2021
)
0.62
"α-lipoic acid combined with valsartan could significantly reduce the level of urinary albumin and oxidative stress, increase antioxidant capacity and alleviate renal function damage in patients with DN, and this will provide a reference for the selection of treatment drugs for DN."( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Cai, J; Jiang, D; Sun, F, 2021
)
0.62
"This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN."( Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022
)
0.72
"This study will evaluate the effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN."( Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022
)
0.72
" Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated."( Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Su, F; Xia, Q, 2023
)
0.91
"To observe the clinical efficacy of Jujing Decoction combined with lipoic acid in the treatment of asthenospermia and teratospermia."( [Efficacy of Jujing Decoction combined with lipoic acid in the treatment of asthenospermia and teratospermia].
Chang, FJ; Chen, Y; Fan, Q; Han, ZY; Sun, ZX; Xue, JG, 2022
)
0.72
"Fifty patients with asthenospermia and teratospermia meeting the inclusion criteria were randomly divided into a blank control (n = 10) and a medication group (n = 40), the former provided with fertility guidance and the latter treated with Jujing Decoction combined with lipoic acid."( [Efficacy of Jujing Decoction combined with lipoic acid in the treatment of asthenospermia and teratospermia].
Chang, FJ; Chen, Y; Fan, Q; Han, ZY; Sun, ZX; Xue, JG, 2022
)
0.72
"Jujing Decoction combined with lipoic acid can significantly improve sperm motility, reduce MAS and DFI and increase the pregnancy rate through antioxidant stress, and has a high clinical safety."( [Efficacy of Jujing Decoction combined with lipoic acid in the treatment of asthenospermia and teratospermia].
Chang, FJ; Chen, Y; Fan, Q; Han, ZY; Sun, ZX; Xue, JG, 2022
)
0.72
"This study investigated the effects of trelagliptin and remogliflozin, alone and in combination with alpha lipoic acid (ALA), on cardiac biomarkers in diabetic cardiomyopathy (DCM)."( Impacts of trelagliptin and remogliflozin alone and in combination with Alpha Lipoic Acid on cardiac function in streptozotocin-induced diabetes mellitus in rats.
Abdullah Ali, M; Kareem Hamad, B; Naji Alhassani, A, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability after the 200 mg dose was 29."( Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers.
Kern, J; Preiss, R; Teichert, J; Tritschler, HJ; Ulrich, H, 1998
)
0.3
" Lung tissue VE content was elevated after loading but VC did not change possibly due to their different bioavailability and saturation kinetics."( Antioxidant loading reduces oxidative stress induced by high-energy impulse noise (blast) exposure.
Armstrong, KL; Cooper, MF; Elsayed, NM; William, MT, 2000
)
0.31
" Exogenous racemic alpha-lipoic acid orally administered for the symptomatic treatment of diabetic polyneuropathy is readily and nearly completely absorbed, with a limited absolute bioavailability of about 30% caused by high hepatic extraction."( Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.
Hermann, R; Preiss, R; Ruus, P; Teichert, J, 2003
)
0.32
"The objective of this study was to determine the impact of prolonged gastric emptying in patients with insulin dependent diabetes mellitus (IDDM) on the bioavailability of the R(+)- and S(-)-thioctic acid (TA) enantiomers."( Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers.
Gleiter, CH; Hermann, R; Niebch, G; Nowak, H; Ruus, P; Wildgrube, HJ, 1998
)
0.71
" The aims of this study were to evaluate the bioavailability of selenium derived from the selenotrisulfide derivative of lipoic acid (LASe) and determine the ability of this compound to be absorbed into skin."( Bioavailability of selenium from the selenotrisulphide derivative of lipoic acid.
Alonis, M; Pinnell, S; Self, WT, 2006
)
0.33
" Both L-selenomethionine and selenate were found to be poor sources of selenium for selenoprotein synthesis in the skin cell model and L-selenomethionine was poorly absorbed into pig skin."( Bioavailability of selenium from the selenotrisulphide derivative of lipoic acid.
Alonis, M; Pinnell, S; Self, WT, 2006
)
0.33
" Improved endothelial function due to alpha-LA was at least partially attributed to recoupling of eNOS and increased NO bioavailability and represents a pharmacological approach to prevent major complications associated with type 2 diabetes."( Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats.
Boarder, MR; Fernandes, R; Louro, T; Nunes, E; Proença, T; Seiça, RM; Sena, CM, 2008
)
0.35
"An open-label, randomized, crossover single-dose study, using two periods and two sequences with a washout period of seven days was conducted to assess the comparative bioavailability of thioctic (alpha-lipoic) acid (ALA) 600 mg formulation and that of a reference formulation."( Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers.
Amenta, F; Mignini, F; Streccioni, V; Tomassoni, D; Traini, E, 2007
)
0.55
" A preliminary study demonstrated the stability and bioavailability were improved by converting RLA to its sodium salt (NaRLA) and pre-dissolving it in water."( The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects.
Carlson, DA; Fischer, SJ; Packer, L; Smith, AR; Young, KL, 2007
)
0.34
"This study was designed to evaluate in healthy volunteers plasma and cellular (in erythrocytes) of three formulations of alpha-lipoic acid (ALA) available in Italy with different rates of absorption, two with a claimed high absorption rate (Byodinoral 600 QR, Tiocronal 600 HR) and one with a claimed prolonged absorption rate (Tiobec 600 retard)."( Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers.
Amenta, F; Mignini, F; Tomassoni, D; Traini, E, 2008
)
0.35
" Lipoic acid (LA) is considered a potent antioxidant which is well absorbed from diet and can easily cross the blood-brain barrier."( Lipoic acid prevents oxidative stress in vitro and in vivo by an acute hyperphenylalaninemia chemically-induced in rat brain.
Coelho, J; da Rosa, A; de Oliveira, A; Dutra-Filho, CS; Moraes, TB; Petrillo, F; Wajner, M; Zanin, F, 2010
)
0.36
" Furthermore, duodenal glutathione and oxidized glutathione (GSH/GSSG) ratios were strongly positively correlated with the apparent calcium absorption rate and the expression of PMCA(1b) and Calbindin-D(9K), whereas reactive oxygen species levels were negatively correlated with them."( Effects of duodenal redox status on calcium absorption and related genes expression in high-fat diet-fed mice.
Cui, J; Le, GW; Shi, YH; Sun, J; Wang, ZP; Xiao, Y,
)
0.13
" Lipoyl vildagliptin might have very high CL/F values and V(d)/F values, which indicated that the bioavailability of this drug might be low or lipoyl vildagliptin might distribute extensively or accumulate in tissues in view of its high liposolubility."( Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Liu, H; Wang, W; Wang, X; Xu, W; Zhang, D, 2010
)
0.36
" However, its typical formulations of salt or micronized crystals cannot satisfy the desired bioavailability requirements for appetite suppression due to low absorption and a short plasma half-life."( Lipoic acid nanoparticles: effect of polymeric stabilizer on appetite suppression.
Kim, HS; Koh, EH; Lee, J; Lee, KU; Park, CH; Park, JY, 2010
)
0.36
" We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants."( Antioxidant therapy: current status and future prospects.
Firuzi, O; Miri, R; Saso, L; Tavakkoli, M, 2011
)
0.37
" In contrast, young males had a tendency for increased bioavailability of R,S-LA."( Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study.
Bemer, B; Butler, JA; Christensen, JM; Dixon, B; Garrard, M; Hagen, TM; Johnson, S; Keith, DJ; Pereira, C; Sudakin, DL, 2012
)
0.38
" Indeed, phenomena such as reduced solubility, lack of gastric stability and hepatic degradation determine a bioavailability of around 30% and a short half-life of ALA."( (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy.
Brufani, M; Figliola, R, 2014
)
0.4
" It is widely accepted that diabetes impairs endothelial nitric oxide synthase (eNOS) activity and increases the production of ROS, thus resulting in diminished NO bioavailability and increased oxidative stress."( Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes.
Ghibu, S; Muresan, A; Rochette, L; Vergely, C, 2015
)
0.42
"Microencapsulation of natural antioxidants in polymeric systems represents a possible strategy for improving the oral bioavailability of compounds that are otherwise poorly soluble."( Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid.
Fresta, M; Musumeci, L; Musumeci, T; Pecora, TM; Pignatello, R, 2016
)
0.43
" Formulations that increase the bioavailability of a-LA have a better potential efficacy as adjuvants for the treatment of these conditions."( Increasing bioavailability of (R)-alpha-lipoic acid to boost antioxidant activity in the treatment of neuropathic pain.
Brufani, M; Citro, G; Maglione, E; Marcuccio, F; Marrese, C; Migliaro, E; Panico, C; Quercio, M; Roncagliolo, F; Salvati, C; Torello, C, 2015
)
0.42
" We previously demonstrated that oral bioavailability of RLA is better than that of SLA."( Investigation of Enantioselective Membrane Permeability of α-Lipoic Acid in Caco-2 and MDCKII Cell.
Hirota, T; Ikuta, N; Okamoto, H; Terao, K; Uchida, R, 2016
)
0.43
"59-fold increase in relative bioavailability as compared to TMX suspension."( Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
Chand, M; Dhaundiyal, A; Jena, SK; Samal, SK; Sangamwar, AT; Sonvane, B, 2016
)
0.43
"α-lipoic acid-stearylamine conjugate-based SLNs have a great potential in enhancing the oral bioavailability of poorly soluble drugs like TMX."( Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
Chand, M; Dhaundiyal, A; Jena, SK; Samal, SK; Sangamwar, AT; Sonvane, B, 2016
)
0.43
" Among different molecules, alpha lipoic acid has been identified as a natural potent antioxidant drug, whose therapeutic efficacy is limited by its many drawbacks, such as fast metabolism, poor bioavailability and high physico-chemical instability."( Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands.
Arena, E; Cacciatore, I; Carbone, C; Di Stefano, A; Marrazzo, A; Pepe, V; Prezzavento, O; Puglisi, G; Turkez, H, 2017
)
0.46
" Its hydrophobic and high crystallization structure results in limited bioavailability in vivo."( α-Lipoic acid stabilized DTX/IR780 micelles for photoacoustic/fluorescence imaging guided photothermal therapy/chemotherapy of breast cancer.
Chen, L; Chen, X; Li, W; Peng, J; Qian, Z; Yang, Q; Zhang, L, 2018
)
0.48
" Results showed that vaginal ALA was well absorbed and distributed."( α-Lipoic Acid Vaginal Administration Contrasts Inflammation and Preterm Delivery in Rats.
Ergur, BU; Fuso, A; Goker, A; Kuscu, K; Micili, SC, 2019
)
0.51
" VNP suffers from low oral bioavailability owing to its low water solubility and extensive first-pass metabolism."( Optimized vinpocetine-loaded vitamin E D-α-tocopherol polyethylene glycol 1000 succinate-alpha lipoic acid micelles as a potential transdermal drug delivery system: in vitro and ex vivo studies.
Ahmed, OA; Ahmed, TA; Aljaeid, BM; Badr-Eldin, SM; El-Say, KM, 2019
)
0.51
"An aqueous dispersion of alpha-lipoic acid (ALA) using octenylsuccinic anhydride-modified high-amylose starch (OS) was prepared, and thermal stability and cellular bioavailability of ALA were compared with those prepared using native high-amylose starch (HA) and beta-cyclodextrin (β-CD)."( Enhanced bioavailability of alpha-lipoic acid by complex formation with octenylsuccinylated high-amylose starch.
Kim, YJ; Lee, SJ; Li, YX; Lim, ST; Reddy, CK, 2019
)
0.51
" Data suggests that ALA has a short half-life and bioavailability (about 30%) triggered by its hepatic degradation, reduced solubility as well as instability in the stomach."( Insights on the Use of α-Lipoic Acid for Therapeutic Purposes.
Akram, M; Antika, G; Berkay Yılmaz, Y; Boyunegmez Tumer, T; Capanoglu, E; Cho, WC; Fawzi Mahomoodally, M; Lobine, D; Martins, N; Riaz, M; Salehi, B; Sharifi-Rad, J; Sharopov, F, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Dapoxetine (DPX), a recently approved drug for the treatment of PE, suffers from low bioavailability with large variability that ranges from 15-76% (mean 42%) after oral administration."( Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation.
Ahmed, OA; El-Say, KM; Mohamed, AI; Omar, AM; Safo, MK, 2019
)
0.51
"The clinical findings suggest 194% enhancement of relative bioavailability of the optimized DPX-loaded NPs, potentially leading to a decrease in therapeutic dose and associated side effects in the treatment of PE."( Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation.
Ahmed, OA; El-Say, KM; Mohamed, AI; Omar, AM; Safo, MK, 2019
)
0.51
" ALA appears to improve endothelial function through increasing the bioavailability of endothelium-derived nitric oxide as well as decreasing oxidative stress and inflammation."( Role of alpha-lipoic acid in vascular function: A systematic review of human intervention studies.
Hajizadeh-Sharafabad, F; Sharifi Zahabi, E, 2022
)
0.72
" From these findings, RLA/SEDDS might be an efficacious dosage option for improving the oral bioavailability as well as nutraceutical properties of RLA."( Self-emulsifying drug delivery system of (R)-α-lipoic acid to improve its stability and oral absorption.
Banik, S; Halder, S; Onoue, S; Sato, H, 2021
)
0.62
"Alpha-lipoic acid (α-LA) is characterized by its unpleasant odor, poor bioavailability and stability."( Chitosan and solid lipid nanoparticles enhance the efficiency of alpha-lipoic acid against experimental neurotoxicity.
Abdel Moneim, MM; El-Bana, MA; El-Naggar, ME; Emam, MA; Fathy, SA; Metwaly, HH; Omara, EA; Soliman, AF, 2022
)
0.72
"Quercetin (QUE)-loaded poly(lipoic acid) nanoparticles (QUE/pLA) were developed to improve chemical stability in the gastrointestinal (GI) tract, oral bioavailability (BA), and pharmacological properties of QUE."( Development of Poly(lipoic acid) Nanoparticles with Improved Oral Bioavailability and Hepatoprotective Effects of Quercetin.
Banik, S; Onoue, S; Sato, H; Yamada, K, 2022
)
0.72
" Although (R)-alpha lipoic acid (ALA) evoked significant pain relief efficacy in a mouse model of multiple sclerosis-associated central neuropathic pain (MS-CNP), this dietary supplement has poor oral bioavailability due to low gastric stability."( Design, synthesis and evaluation of alpha lipoic acid derivatives to treat multiple sclerosis-associated central neuropathic pain.
Blanchfield, JT; Carpinelli de Jesus, M; Jones, A; Khan, N; Kong, D; Saqer, AA; Smith, MT; Williams, CM, 2022
)
0.72

Dosage Studied

Thioctic acid at an oral dosage of 800 mg/day for 4 months significantly improved cardiac autonomic neuropathy in type 2 diabetic patients.

ExcerptRelevanceReference
" Unexpected inhibition by free lipoic acid resulted in a biphasic dose-response curve with a detection limit of 5 x 10(-6) M lipoic acid."( Homogeneous enzyme immunoassay for lipoic acid based on the pyruvate dehydrogenase complex: a model for an assay using a conjugate with one ligand per subunit.
Bachas, LG; MacLean, AI, 1991
)
0.28
"Polylactic acid-polylipoic acid nanospheres (PLA-PLIA-NS) were prepared, and their properties as drug targeting dosage forms were evaluated."( Preparation of polylactic acid-polylipoic acid nanospheres as drug targeting carriers.
Arai, K; Machida, Y; Nagai, T; Nambu, N; Nambu, Y; Takayama, K; Ueda, H, 1987
)
0.27
" The mean silybin dosage was 33 mg/kg body weight/day; the mean duration of silybin therapy was 81."( [Pharmacotherapy of Amanita phalloides poisoning using silybin].
Csomos, G; Fuhrmann, M; Hruby, K; Thaler, H, 1983
)
0.27
" Thioctic acid provoked an upward shift of the glucose-uptake insulin dose-response curve."( Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway.
Estrada, DE; Ewart, HS; Klip, A; Ramlal, T; Tritschler, H; Tsakiridis, T; Volchuk, A, 1996
)
1.44
" The racemate of lipoic acid at high dosage (350 mg/kg body weight) reduced the life span significantly."( Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed mice.
Ackermann, H; Freisleben, HJ; Lehr, F; Neeb, A, 1997
)
0.3
" In conclusion, this study suggests that short-term administration of LA at high dosage to normal and diabetic rats causes an inhibition of gluconeogenesis secondary to an interference with hepatic fatty acid oxidation."( Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats.
Bashan, N; Gutman, A; Khamaisi, M; Potashnik, R; Rudich, A; Tritschler, HJ, 1999
)
0.3
"The excretion and biotransformation of rac-alpha-lipoic acid (LA), which is used for the symptomatic treatment of diabetic polyneuropathy, were investigated following single oral dosing of [(14)C]LA to mice (30 mg/kg), rats (30 mg/kg), dogs (10 mg/kg), and unlabeled LA to humans (600 mg)."( New metabolic pathways of alpha-lipoic acid.
Engel, J; Hempel, R; Hermann, R; Kronbach, T; Peter, G; Schupke, H; Wessel, K, 2001
)
0.31
"The purpose of this study was the design and evaluation of a sustained release dosage form for the oral administration of alpha-lipoic acid."( Development of a sustained release dosage form for alpha-lipoic acid. I. Design and in vitro evaluation.
Bernkop-Schnürch, A; Clausen, AE; Hanel, R; Schuhbauer, H, 2004
)
0.32
"Within this study an oral sustained release dosage form of alpha-lipoic acid (thioctic acid) has been generated and evaluated in healthy volunteers."( Development of a sustained release dosage form for alpha-lipoic acid. II. Evaluation in human volunteers.
Bernkop-Schnürch, A; Kratzel, M; Marschütz, M; Reich-Rohrwig, E; Schuhbauer, H, 2004
)
0.55
" Depending on post-mitotic tissue type and dosage of LA, the prooxidant effects of LA supplementation, should be considered in future studies."( Effect of alpha-lipoic acid supplementation on markers of protein oxidation in post-mitotic tissues of ageing rat.
Akçay, T; Altuğ, T; Cakatay, U; Kayali, R,
)
0.13
" However, a randomized, double-blind, placebo-controlled, multicenter trial showed that thioctic acid at an oral dosage of 800 mg/day for 4 months significantly improved cardiac autonomic neuropathy in type 2 diabetic patients."( The role of antioxidant micronutrients in the prevention of diabetic complications.
Bonnefont-Rousselot, D, 2004
)
0.55
" (c) Ethanol mediated a dose-response enhancement of the contractile dysfunctions caused by in vitro ischemia."( Effect of ethanol on the response of the rat urinary bladder to in vitro ischemia: protective effect of alpha-lipoic acid.
Danek, M; Haugaard, N; Levin, RM; Whitbeck, C, 2005
)
0.33
" The protective effect of LA was found to be stronger at a dose of 200 mg/kg body weight than 100 mg/kg body weight dosage with respect to the above results, indicating the dose dependent effect of LA."( Salubrious effects of lipoic acid against adriamycin-induced clastogenesis and apoptosis in Wistar rat bone marrow cells.
Kumarasamy, P; Prahalathan, C; Saravanan, R; Selvakumar, E; Varalakshmi, P, 2006
)
0.33
" In some diseases supplementation of antioxidants in the proper form and dosage may be irrelevant."( [The role of antioxidants in prevention].
Feher, J; Lengyel, G; Nagy, V; Németh, E, 2006
)
0.33
" The only notable finding in rats of both sexes dosed at 180 mg/kg bw/day was a reduction in food intake relative to the controls and a concomitant decrease in body weight."( Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study.
Cremer, DR; Lynch, B; Rabeler, R; Roberts, A, 2006
)
0.33
" Repeated dosing was administered intraperitoneally every 4 to 6 hours for 48 hours."( Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model.
Betten, DP; Clark, RF; Favata, M; Hernandez, M; Richardson, WH; Riffenburgh, RH; Tanen, DA; Tong, TC, 2007
)
0.55
" The current study extends earlier findings from this laboratory and presents PK data for the 600-mg oral dosing of 12 healthy adult subjects given NaRLA."( The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects.
Carlson, DA; Fischer, SJ; Packer, L; Smith, AR; Young, KL, 2007
)
0.34
"Twenty-eight patients, 17 women and 11 men, aged 40-70 years, with distal sensory-motor diabetic neuropathy of the lower extremities were treated with berlition, an alpha-lipoic acid preparation, in dosage 600 mg daily during 3 months."( [Implication of alpha-lipoic acid preparations in the treatment of diabetic neuropathy].
Al'-Zamil', MKh; Brezheva, EV, 2008
)
0.35
" Interestingly, bell-shaped dose-response curves emerged."( Opposite effects of alpha-lipoic acid on antioxidation and long-term potentiation in control and chronically lead-exposed rats.
Chen, XT; Liu, J; Ruan, DY; Tang, ML; Wang, HL; Wu, CY; Yin, ST, 2008
)
0.35
" It has been shown that berlition in dosage 300 mg twice daily for 3 months exerts a significant positive effect on the state of sensory and motor functions as well as neurophysiologic disturbances."( [The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy].
Al-Zamil, MKh, 2008
)
0.35
" However, lipoic acid distribution in brain has not been investigated via oral dosing in human subjects or animals."( Distribution study of orally administered lipoic acid in rat brain tissues.
Browne, ER; Chan, EC; Chng, HT; Goh, CW; Neo, AH; New, LS, 2009
)
0.35
" Further considerations for dose-response relationships, duration of supplementation, and susceptible biomarkers are required."( Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients.
Bae, SC; Jung, WJ; Lee, EJ; Sung, MK; Yu, R, 2009
)
0.35
" The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid."( Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.
Alvarez, L; Bourdette, DN; Cherala, G; Koop, DR; Marracci, GH; Munar, MY; Shinto, L; Stuber, LE; Yadav, V, 2010
)
0.36
"Based on the currently available evidence, when given intravenously at a dosage of 600 mg once daily over a period of three weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A)."( Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?
Alkhalaf, A; Bilo, HJ; Kleefstra, N; Mijnhout, GS, 2010
)
0.36
" Eight full-thickness bladder strips were isolated from each of 4 treated and 4 control rabbit bladders, and a dose-response curve to H(2)O(2) (0."( Differential effects of coenzyme Q10 and α-lipoic acid on two models of in vitro oxidative damage to the rabbit urinary bladder.
Leggett, RE; Levin, RM; Li, HT; Schuler, C, 2011
)
0.37
"A significant effect of dosage was observed regardless of delivery method."( Pharmacokinetics of orally administered DL-α-lipoic acid in dogs.
Avila, A; Gross, KL; Joshi, DK; Zicker, SC, 2010
)
0.36
" In the chronic study, two of four rats suddenly died by the repeated dosing of ATO, whereas no deaths were observed in combination with LA."( Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Ando, H; Fujimura, A; Hosohata, K; Koshimizu, TA; Kumazaki, M; Oshima, Y; Sasaki, A; Ushijima, K, 2011
)
0.37
" These results provide important information in terms of dosage safety and biocompatibility of DHLA to facilitate its further use as a precursor for biomaterial preparation."( Impact of dihydrolipoic acid on mouse embryonic stem cells and related regulatory mechanisms.
Chan, WH; Chang, WH; Houng, WL; Hsieh, JT; Lee, CH; Li, PW; Lin, CA; Shen, JL; Yeh, HI, 2013
)
0.39
"A daily dosage of 600 mg ALA does not prevent the occurrence of CSME in IDDM patients."( Alpha-lipoic acid for the prevention of diabetic macular edema.
Gerss, J; Hammes, HP; Haritoglou, C; Kampik, A; Ulbig, MW, 2011
)
0.37
" A single dose of 600 mg of dose ALA did not induce any protection on the TTS(2) induced by a 90 dB HL 3 kHz tone, while 10 days of therapeutic dosage assumption of ALA was associated with significant protection at 6 kHz."( The effect of alpha-lipoic acid on temporary threshold shift in humans: a preliminary study.
D'Elia, A; Dicorato, A; Matera, V; Quaranta, A; Quaranta, N, 2012
)
0.38
"The effects of cadmium (Cd) and arsenic (As), dosed alone or in combination have been poorly investigated in crustaceans."( The role of lipoic acid in the protection against of metallic pollutant effects in the shrimp Litopenaeus vannamei (Crustacea, Decapoda).
Fattorini, D; Lobato, RO; Monserrat, JM; Nunes, SM; Regoli, F; Ventura-Lima, J; Wasielesky, W, 2013
)
0.39
" Dosage of the drug was 600 mg daily."( [Efficacy of thiolepta in diabetic polyneuropathy: results of the study ETIKA].
Fokina, AS; Golovacheva, VA; Kochetov, AG; Strokov, IA, 2013
)
0.39
"020) with less daily insulin dosage and was more powerful in lowering total cholesterol, increasing AIR and HOMA β-cell function, whereas reduction of IMCL in the soleus was more obvious in the rosiglitazone group but not in the metformin group."( Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Chen, A; Deng, W; Fang, D; Huang, Z; Li, H; Li, Y; Liu, J; Liu, L; Wan, X; Wei, G, 2013
)
0.39
" High attrition rates due to poor patient compliance and manner of dosage administration in this trial demonstrated a lack of feasibility for this intervention."( Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Dakhil, SR; Eng, C; Fisch, MJ; Forman, A; Gilman, P; Guo, Y; Jones, D; Mills, GM; Noga, SJ; Overman, MJ; Palmer, JL; Velasco, MR; Weiss, M, 2014
)
0.4
"In targeted photodynamic therapy (tPDT), photosensitizers (PS) are targeted to disease tissue to reduce the dosage of PS and in addition to reduce the photo damage to the non-target tissue."( Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles.
Irudayaraj, J; Manorama, SV; Narsireddy, A; Rao, NM; Vijayashree, K, 2014
)
0.4
" Dosing with LA protected photoreceptors, decreasing the numbers of TUNEL-positive photoreceptors and increasing the number of surviving photoreceptors."( Systemic administration of the antioxidant/iron chelator α-lipoic acid protects against light-induced photoreceptor degeneration in the mouse retina.
Dunaief, JL; Li, Y; Song, D; Song, Y; Su, G; Wang, C; Zhao, L, 2014
)
0.4
" Both α-lipoic acid and etanercept markedly reduced cerebral infarct, blood-brain barrier disruption, and neurological motor deficits with the former drug being more effective with the dosage used."( Inhibition of Peripheral TNF-α and Downregulation of Microglial Activation by Alpha-Lipoic Acid and Etanercept Protect Rat Brain Against Ischemic Stroke.
Chang, CP; Chio, CC; Huang, CC; Lin, MT; Lin, NK; Tsai, KJ; Wu, MH, 2016
)
0.43
" The subjects were divided into two groups: Group A, treated with an association of 1 g myo-inositol, 5 mg monacolin K and 400 mg lipoic acid for 6 months; Group B, treated with a double dosage of 2 g myo-inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months."( Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015
)
0.42
"The results have shown good efficacy of both dosages, although women treated with a double dosage of myo-inositol, monacolin K and lipoic acid showed a significantly greater improvement in terms of lipid parameters and those connected with hyperandrogenism."( Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015
)
0.42
" This study was designed to evaluate the efficacy of CMX-2043 in an animal model of myocardial IRI and to establish effective dosing conditions."( CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury.
Baguisi, A; Beeuwkes, R; Casale, RA; Kates, SA; Lader, AS; Stewart, K, 2016
)
0.43
"The addition of ALA/n-3 PUFAs to amitriptyline treatment in patients with VBD/PBS appears to improve outcomes and may allow for a lower dosage of amitriptyline, which may lead to fewer adverse effects."( Alpha Lipoic Acid Plus Omega-3 Fatty Acids for Vestibulodynia Associated With Painful Bladder Syndrome.
Felice, R; Gambini, D; Graziottin, A; Murina, F, 2017
)
0.46
" Group II was intraperitoneally administered saline solution at the same dosage and over the same period."( Effect of alpha-lipoic acid on endometrial implants in an experimental rat model.
Bayraktar, S; Özcan, O; Özgür, T; Pınar, N; Soylu Karapınar, O, 2017
)
0.46
"ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes."( Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
Della Casa, D; Despini, G; Genazzani, AD; Manzo, A; Napolitano, A; Prati, A; Shefer, K; Simoncini, T, 2018
)
0.48
" Serial blood samples were collected up to 24 hours after the last dosing in each period."( Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers.
Ahn, LY; Lee, H; Lim, KS; Rhee, SJ; Yu, KS, 2018
)
0.71
" Also, ALA's liquid formulations are associated with greater plasma concentration and bioavailability as compared to its solidified dosage form."( Insights on the Use of α-Lipoic Acid for Therapeutic Purposes.
Akram, M; Antika, G; Berkay Yılmaz, Y; Boyunegmez Tumer, T; Capanoglu, E; Cho, WC; Fawzi Mahomoodally, M; Lobine, D; Martins, N; Riaz, M; Salehi, B; Sharifi-Rad, J; Sharopov, F, 2019
)
0.51
"There are numerous trials reported the effect of alpha-lipoic acid (ALA) on obesity measurements; while no summarised dose-response meta-analysis is available to address the effects of dose and duration of ALA supplementation on obesity measurements."( Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials.
Abbasalizad Farhangi, M; Vajdi, M, 2020
)
0.56
" Two class and dose-response meta-analysis were performed to data analysis."( Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials.
Abbasalizad Farhangi, M; Vajdi, M, 2020
)
0.56
"Twenty-four male Wistar-Kyoto rats (220-240 g, 12 weeks old) were dosed with 50 μL of 10 nm GNPs administered intraperitoneally with or without 200 mg/kg/day Vit E or 200 mg/kg/day α-Lip."( The Protective Roles of Vitamin E and α-Lipoic Acid Against Nephrotoxicity, Lipid Peroxidation, and Inflammatory Damage Induced by Gold Nanoparticles.
Abdelhalim, MAK; Al-Mohy, YH; Ghannam, MM; Qaid, HA, 2020
)
0.56
" α-lipoic acid was given to the mice intraperitoneally at a dosage of 50 μg/g body weight every other day."( Otoprotective Effects of α-lipoic Acid on A/J Mice With Age-related Hearing Loss.
Han, F; Huang, S; Li, P; Liu, T; Lu, P; Shang, W; Sun, X; Xie, Y; Xu, A; Zhao, M; Zhou, B, 2020
)
0.56
"To identify possible interactions of components in dosage forms, studies are usually carried out at the stage of pharmaceutical development."( Investigation of thioctic acid, magnesium stearate and pyridoxine hydrochloride compatibility.
Almakaiev, M; Budianska, L; Lisetski, L; Sofronov, D; Vashchenko, O, 2020
)
0.9
"1% and 80%, respectively, also far better than those of free CPT at the same dosage (TIR: 46%, SR: 0%)."( Cross-linked (R)-(+)-lipoic acid nanoparticles with prodrug loading for synergistic cancer therapy.
Chen, Y; Liao, C; Yang, F; Zhang, J; Zhang, S, 2021
)
0.62
" Improvements in DCNVA were sustained at 5 and 7 months after UNR844 dosing ceased."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.62
" From these findings, RLA/SEDDS might be an efficacious dosage option for improving the oral bioavailability as well as nutraceutical properties of RLA."( Self-emulsifying drug delivery system of (R)-α-lipoic acid to improve its stability and oral absorption.
Banik, S; Halder, S; Onoue, S; Sato, H, 2021
)
0.62
" Orally dosed QUE/pLA (50 mg QUE/kg) in rats exhibited significantly prolonged systemic exposure, possibly due to the sustained release of QUE."( Development of Poly(lipoic acid) Nanoparticles with Improved Oral Bioavailability and Hepatoprotective Effects of Quercetin.
Banik, S; Onoue, S; Sato, H; Yamada, K, 2022
)
0.72
" The dosage of alpha-lipoic acid was determined for each of the groups."( EFFECTS OF ALPHA-LIPOIC ACID ON GLYCEMIC STATUS IN 2 TYPE DIABETES PATIENTS WITH СHRONIC CORONARY SYNDROME.
Altunina, N; Bondarchuk, O, 2022
)
0.72
"Advantageous application of the validated HPLC method for the concurrent analysis of ALO/THA in their tablet dosage form was accomplished."( Forced Degradation and Stability-Indicating Study for the Binary Mixture of Allopurinol and Thioctic Acid Using Validated HPLC-DAD Method.
Abdel-Khalek, MM; Abdelhamid, AG; Belal, TS; El-Kafrawy, DS, 2023
)
1.13
" Our meta-analysis is aimed at evaluating the effects of oral-administered ALA versus a placebo in patients with DSPN and determining the optimal dosage for this treatment."( Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Chen, C; Hsieh, RY; Huang, IC; Sung, JY, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (108 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements46
Beauty & Personal Care8
Professional Supplements18
Active Lifestyle & Fitness31
Weight Management2
Herbs, Botanicals & Homeopathy3

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
1Life Science NAD+ Longevity Blood Sugar Support -- 60 Veggie Caps1Life ScienceVitamins & SupplementsUrolithin A, Berberine HCl, Chromium, NAD +, NMN, Alpha-Lipoic Acid, Vanadium2024-11-29 10:47:42
Alba Botanica Even & Bright Renewing Cream -- 2 ozAlbaBeauty & Personal Careorange, amyl cinnamal, citric acid, ascorbyl palmitate, allantoin, ascorbyl glucoside, ascorbic acid, cetyl alcohol, citric acid, coumarin, coumarin, tocopherol, panthenol, erythritol, triethyl citrate, tocopherol, glycerin, limonene, linalyl acetate, phenoxyethanol, potassium hydroxide, sodium benzoate, sodium citrate, sodium hydroxide, sorbitol, squalane, stearic acid, stearyl alcohol, thioctic acid2024-11-29 10:47:42
Allergy Research Group LipoPhos EDTA -- 2 fl ozAllergy Research GroupProfessional SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Allergy Research Group NAC Enhanced Antioxidant Formula -- 90 TabletsAllergy Research GroupProfessional SupplementsN-Acetyl Cysteine, Trimethylglycine, Trimethylglycine, Alpha-Lipoic Acid2024-11-29 10:47:42
ALLMAX Nutrition TestoFX Testosterone Booster and Cortisol Blocker -- 90 CapsulesALLMAX NutritionActive Lifestyle & FitnessMyo-Inositol, Alpha-Lipoic Acid, Withania somnifera2024-11-29 10:47:42
Amazing Nutrition Amazing Formulas Advanced Lipoic Acid -- 600 mg - 120 CapsulesAmazing NutritionVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Amazing Nutrition Amazing Formulas Advanced Lipoic Acid -- 600 mg - 60 CapsulesAmazing NutritionVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Amy Myers MD Liver Support -- 60 CapsulesAmy Myers MDProfessional SupplementsSelenium, Alpha-Lipoic Acid2024-11-29 10:47:42
Animal Non-Hormonal M-Stak Accelerator Pill Packs -- 21 PacksAnimalActive Lifestyle & FitnessAcetyl L-Carnitine, Caffeine Anhydrous, L-Isoleucine, Phytosterols, L-Taurine, Alpha-Lipoic Acid, L-Valine2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 30 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 44 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal Stak All-in-1 Pill Packs -- 21 PacketsAnimalActive Lifestyle & FitnessDiindolylmethane, Astaxanthin, Coenzyme Q10, L-Glutamine, Glycine, Vitamin B6, Quercetin Dihydrate, Alpha-Lipoic Acid, Vitamin B62024-11-29 10:47:42
Best Naturals Acetyl L-Carnitine Alpha Lipoic Acid -- 750 mg - 120 CapsulesBest NaturalsVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Best Naturals Alpha Lipoic Acid -- 200 mg - 120 CapsulesBest NaturalsVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Best Naturals Alpha Lipoic Acid -- 300 mg - 120 CapsulesBest NaturalsVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Best Naturals Alpha Lipoic Acid -- 600 mg - 240 CapsulesBest NaturalsVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Bio Nutrition Blood Sugar Wellness -- 60 Vegetarian CapsulesBio NutritionVitamins & SupplementsAlpha Lipoic Acid, Vanadyl Sulfate2024-11-29 10:47:42
Bio Nutrition Liver Wellness -- 60 Vegetarian CapsulesBio NutritionVitamins & SupplementsSelenium, Alpha Lipoic Acid2024-11-29 10:47:42
Bio Nutrition Stomach Wellness -- 60 Vegetarian CapsulesBio NutritionVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
BioSchwartz Glutathione Complex -- 60 CapsulesBioSchwartzVitamins & SupplementsVitamin C, Quercetin, Selenium, Alpha-Lipoic Acid2024-11-29 10:47:42
Codeage Berberine Phytosome-Indian Barberry Berberine HCL-Alpha Lipoic Acid-Phospholipids -- 60 CapsulesCodeageProfessional SupplementsBerberine HCl, Alpha Lipoic Acid2024-11-29 10:47:42
Codeage Liposomal Vitamin C 1500 mg - Immune System Support Formula - Bioflavonoids -- 180 Capsules Each / Pack of 2CodeageProfessional SupplementsVitamin C, Quercetin Dihydrate, Alpha-Lipoic Acid2024-11-29 10:47:42
Codeage Liposomal Vitamin C 1500 mg Supplement with Zinc Elderberry Quercetin -- 180 CapsulesCodeageProfessional SupplementsVitamin C, Quercetin Dihydrate, Alpha-Lipoic Acid2024-11-29 10:47:42
CSI Alpha Lipoic Acid Facial Complex with BioPerine® -- 60 CapsulesCosmeceutical Sciences Institute (CSI)Vitamins & SupplementsBiotin, Alpha-Lipoic Acid2024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 120 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, d-calcium pantothenate, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 60 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Cymbiotika Liposomal Glutathione Organic Citrus Berry -- 25 ServingsCymbiotikaVitamins & SupplementsCoQ10, Vitamin B2, Alpha-Lipoic Acid2024-11-29 10:47:42
DaVinci Laboratories Daily Best™ Ultra Multivitamin -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Healthy Eyes -- 90 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Vitamin E, Vitamin E, Lutein, Lycopene, Quercetin, Vitamin A, Riboflavin, Selenium, Taurine, Alpha-Lipoic Acid, Vitamin B12, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Spectra Man Multi -- 120 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Derma E Firming DMAE Moisturizer -- 2 ozDerma EBeauty & Personal Careallantoin, caffeine, cetyl alcohol, dimethyl MEA, panthenol, ethylhexylglycerin, glyceryl stearate, glycerin, dimethicone, resveratrol, retinol, sodium hydroxide, stearic acid, stearyl alcohol, thioctic acid, ubiquinone2024-11-29 10:47:42
Designs for Sport Mito NRG Complex - NSF Certified for Sport -- 120 Vegetarian CapsulesDesigns for SportProfessional SupplementsCoenzyme Q10, Creatine, L-Carnitine, Malic Acid, Manganese, Niacin, Pantethine, Vitamin B6, Trans-Resveratrol, Riboflavin, D-Ribose, Succinic Acid, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Deva Vegan Hair Nails and Skin -- 90 TabletsDevaVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, L-cysteine, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B3, PABA, Vitamin B5, Vitamin B6, Vitamin B2, Beta Sitosterol, Vitamin B1, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Liversup -- 675 mg - 90 TabletsDevaVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Divine Health Carb Assist -- 60 CapsulesDivine HealthWeight ManagementBiotin, Chromium, Alpha Lipoic Acid, Vanadyl Sulfate2024-11-29 10:47:42
Douglas Laboratories Berberine Balance -- 60 Vegetarian CapsulesDouglas LaboratoriesProfessional SupplementsBerberine HCl, Alpha Lipoic Acid2024-11-29 10:47:42
Emerald Labs CoEnzymated Complete plus 2-Daily Multi -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsLipase, Beta Carotene, Biotin, Boron, Cellulase, Vitamin D3, Chromium, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, P-5-P, Pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, R-5-P, Rutin, Selenium, Vitamin B1, Alpha Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Complete Clinical Plus Multi -- 120 Vegetable CapsulesEmerald LabsVitamins & SupplementsBeta Carotene, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, P-5-P, Pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, R-5-P, Rutin, Selenium, Vitamin B1, Alpha Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Prenatal 1-Daily Multi -- 30 Vegetable CapsulesEmerald LabsVitamins & SupplementsBiotin, Boron, Vitamin D3, Chromium, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Prenatal 1-Daily Multi -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsLipase, Beta Carotene, Biotin, Boron, cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Enzyme Science Digest Gold -- 240 CapsulesEnzyme ScienceProfessional Supplements CoQ10, Magnesium citrate, Alpha Lipoic Acid2024-11-29 10:47:42
Enzyme Science Digest Gold -- 90 CapsulesEnzyme ScienceProfessional Supplements CoQ10, Magnesium citrate, Alpha Lipoic Acid2024-11-29 10:47:42
Enzyme Science Stem XCell Pro -- 60 CapsulesEnzyme ScienceProfessional SupplementsCarnosine, Cellulase, Vitamin D3, Alpha-Lipoic Acid2024-11-29 10:47:42
Enzymedica Stem XCell -- 60 Vegetarian CapsulesEnzymedicaVitamins & SupplementsCarnosine, Cellulase, Vitamin D3, Alpha-Lipoic Acid2024-11-29 10:47:42
Evlution Nutrition VitaMode -- 120 TabletsEvlution NutritionActive Lifestyle & Fitness Lipase, PABA, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
ForestLeaf Red Yeast Rice + CoQ10 -- 1215 mg - 90 CapsulesForestLeafVitamins & SupplementsCoenzyme Q10, Alpha-Lipoic Acid2024-11-29 10:47:42
Healths Harmony Blood Sugar Capsules with Cinnamon Bitter Melon and Chromium -- 120 CapsulesHealths HarmonyHerbs, Botanicals & HomeopathyVitamin C, Biotin, Chromium, Vitamin E, Vitamin E, microcrystalline cellulose, Manganese, Taurine, Alpha Lipoic Acid, Vanadium2024-11-29 10:47:42
Irwin Naturals Ginkgo Smart -- 120 Liquid SoftgelsIrwin NaturalsHerbs, Botanicals & HomeopathyAcetyl L-Carnitine, Trimethylglycine, Trimethylglycine, Choline, Dimethylaminoethanol, glycerin, Alpha-Lipoic Acid, Vinpocetine2024-11-29 10:47:42
Irwin Naturals Ginkgo Smart® -- 60 Liquid SoftgelsIrwin NaturalsHerbs, Botanicals & HomeopathyAcetyl L-Carnitine, Trimethylglycine, Trimethylglycine, Choline, Dimethylaminoethanol, glycerin, Alpha-Lipoic Acid, Vinpocetine2024-11-29 10:47:42
Jarrow Formulas Alpha Lipoic Sustain With Biotin -- 120 TabletsJarrow FormulasVitamins & SupplementsBiotin, carbomer, glyceryl behenate, microcrystalline cellulose, stearic acid, Alpha-Lipoic Acid, Calcium phosphate2024-11-29 10:47:42
Jason C Effects Powered By Ester-C Creme -- 2 ozJasonBeauty & Personal Careallantoin, alpha-isomethyl ionone, benzyl alcohol, benzyl benzoate, benzyl salicylate, gluconolactone, bisabolol, calcium ascorbate, cetearyl alcohol, cetyl alcohol, cinnamyl alcohol, citral, coumarin, coumarin, panthenol, glycerin, dimethicone, hexyl cinnamal, hydroxyisohexyl 3-cyclohexene carboxaldehyde, calcium carbonate, limonene, linalool, phenoxyethanol, potassium hydroxide, sodium benzoate, stearic acid, thioctic acid2024-11-29 10:47:42
Klean Athlete Klean Antioxidant - NSF Certified for Sport -- 90 Vegetarian CapsulesKlean AthleteProfessional SupplementsVitamin C, Astaxanthin, Biotin, microcrystalline cellulose, calcium carbonate, Alpha-Lipoic Acid2024-11-29 10:47:42
Klean Athlete Klean Focus - NSF Certified for Sport -- 90 Vegetarian CapsulesKlean AthleteProfessional SupplementsBiotin, Alpha-GPC, microcrystalline cellulose, calcium carbonate, Lutein, Alpha Lipoic Acid2024-11-29 10:47:42
Lean1 Nutrition 53 Fat Burning Meal Replacement Chocolate -- 2 lbsLean1Weight ManagementD-alpha-tocopherol acetate, Vitamin C, Biotin, D-calcium pantothenate, Chloride, vitamin D3, Chromium, copper gluconate, Vitamin E, beta glucans, ferrous fumarate, Folate, Vitamin E, L-glutamine, Iodine, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, Phosphorus, phytosterols, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium molybdate, sodium selenate, taurine, thiamine hydrochloride, Thiamin, alpha lipoic acid, calcium phosphate, cyanocobalamin, Vitamin B6, phytonadione, Vitamin K, zinc oxide2024-11-29 10:47:42
Life Extension Two-Per-Day Capsules -- 120 CapsulesLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCl, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life Extension Two-Per-Day Tablets -- 120 TabletsLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, glycerin, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCI, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
MRM Complete E -- 60 SoftgelsMRMVitamins & SupplementsVitamin C, d-Beta Tocopherol, Coenzyme Q10, d-Alpha-Tocopherol, d-delta tocopherol, d-Gamma Tocopherol, d-Gamma Tocotrienol, Vitamin E, glycerin, Phytosterols, Alpha-Lipoic Acid, d-Alpha Tocotrienol2024-11-29 10:47:42
MRM Liver X™ -- 60 Vegan CapsulesMRMVitamins & SupplementsBetaine Anhydrous, Vitamin E, Vitamin E, Alpha-Lipoic Acid, Vitamin B122024-11-29 10:47:42
MuscleTech Cell-Tech Creatine Formula Fruit Punch -- 3 lbsMuscleTechActive Lifestyle & Fitnessacesulfame-potassium, acesulfame-potassium, L-Alanine, amaranth, Vitamin C, L-Isoleucine, Vitamin B6, Sugar, Taurine, Alpha lipoic acid, sucralose, L-Valine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Natrol Alpha Lipoic Acid -- 300 mg - 50 CapsulesNatrolVitamins & SupplementsAlpha-Lipoic Acid2024-11-29 10:47:42
Natrol Alpha Lipoic Acid Time Release -- 600 mg - 45 TabletsNatrolVitamins & Supplements Microcrystalline cellulose, methylcellulose, stearic acid, Alpha-Lipoic Acid2024-11-29 10:47:42
Natural Stacks Professional Formula ALA+ -- 60 Vegan CapsulesNatural StacksProfessional Supplementsascorbyl palmitate, Vitamin C, Lycopene, Phosphorus, Alpha-Lipoic Acid2024-11-29 10:47:42
Neuliven Health Natural Glucocil Total Blood Sugar Optimizer -- 120 SoftgelsNeuliven HealthVitamins & Supplements leaf, Glycerin, Alpha-Lipoic Acid, Titanium Dioxide2024-11-29 10:47:42
NutraBio MultiSport for Men -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutraBio MultiSport for Women -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriBiotic Body Creme -- 8 fl ozNutriBioticBeauty & Personal Careascorbyl glucoside, vitamin C, carbomer, cetyl alcohol, DMAE, ethylhexylglycerin, glyceryl stearate, glycerin, dimethicone, phenoxyethanol, stearic acid, alpha lipoic acid, tocotrienol2024-11-29 10:47:42
NutriBiotic Face Creme -- 2 fl ozNutriBioticBeauty & Personal Careallantoin, vitamin C, benzyl alcohol, vitamin D3, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycerol monolaurate, phenoxyethanol, retinyl palmitate, squalene, stearic acid, stearyl alcohol, alpha lipoic acid, tocotrienol, tromethamine2024-11-29 10:47:42
NutriBiotic Skin Serum -- 1 fl ozNutriBioticBeauty & Personal Careascorbyl palmitate, CoQ10, tocopherol, DMAE, tocopherol, glycerin, imidazolidinyl urea, linalool, linoleic acid, mannitol, methylparaben, phenoxyethanol, propylparaben, retinyl palmitate, betasitosterol, sodium metabisulfite, alpha lipoic acid, tocotrienol, ubiquinone2024-11-29 10:47:42
NutriCology Ocudyne II -- 200 CapsulesNutriCologyVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Glycine, microcrystalline cellulose, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Nutricost Alpha Lipoic Acid Capsules -- 600 mg - 240 CapsulesNutricostVitamins & Supplements Di-calcium phosphate, microcrystalline cellulose, Alpha-Lipoic Acid2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 150 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 240 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 90 TabletsOptimum NutritionActive Lifestyle & FitnessPABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, glycerine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Women Multivitamin for Women -- 120 CapsulesOptimum NutritionActive Lifestyle & FitnessAlpha-Carotene, Vitamin C, kelp, Biotin, Chromium, Cryptoxanthin, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Isoflavone, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, citrate, sodium selenate, citrate, Thiamin, Alpha-Lipoic Acid, calcium phosphate, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Women Multivitamin for Women -- 60 CapsulesOptimum NutritionActive Lifestyle & FitnessAlpha-Carotene, Vitamin C, kelp, Biotin, Chromium, Cryptoxanthin, Vitamin E, Folic Acid, Vitamin E, microcrystalline cellulose, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, potassium iodide, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Source Naturals Alpha Lipoic Acid Time Release -- 300 mg - 120 TabletsSource NaturalsVitamins & Supplements Dibasic calcium phosphate, microcrystalline cellulose, Alpha-Lipoic Acid2024-11-29 10:47:42
Terry Naturally Healthy Feet & Nerves -- 60 CapsulesTerry NaturallyVitamins & SupplementsBiotin, Chromium, Folate, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Terry Naturally Healthy Feet & Nerves™ -- 120 CapsulesTerry NaturallyVitamins & SupplementsBenfotiamine, Biotin, Chromium, Folate, cellulose powder, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Acai Berry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Cherry Lime -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Cranberry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, tartaric acid, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Grape -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Guava Passion Fruit -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, glycosides, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, steviol, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Lemon Lime -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Mixed Berry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Orange Blast -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnessorange, citric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Pineapple Coconut -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, sugar, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Pomegranate Blueberry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Raspberry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Tangerine -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak + Immunity Lemon Berry -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Vitamin D3, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, vanilla, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Sugar Free Citrus -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnesscitric acid, Vitamin C, Boron, Chloride, Chromium, citric acid, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Xylitol2024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina Power Pak Sugar Free Orange Mango -- 30 PacketsTrace Minerals ResearchActive Lifestyle & Fitnessorange, Vitamin C, Boron, Chloride, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Xylitol2024-11-29 10:47:42
Trace Minerals Research Electrolyte Stamina PowerPak Watermelon -- 30 PacketsTrace Minerals ResearchActive Lifestyle & FitnessVitamin C, Boron, Chloride, Chromium, Folate, malic acid, Manganese, Niacin, Pantothenic Acid, Potassium Citrate, Vitamin B6, Selenium, tartaric acid, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
TruSkin Eye Cream -- 0.5 ozTruSkinBeauty & Personal Carebutylene glycol, ascorbic acid, carbomer, cetostearyl alcohol, cetyl alcohol, coq10, glyceryl stearate, glycolic acid, isopropyl palmitate, lactic acid, phenoxyethanol, phytic acid, propylene glycol, potassium stearate, stearyl alcohol, thioctic acid2024-11-29 10:47:42
Vibrant Health Metabolic Vibrance -- 90 CapsulesVibrant HealthVitamins & SupplementsAscorbyl Palmitate, Acetyl L-Carnitine, N-Acetyl Cysteine, Vitamin C, Vitamin D3, Chromium, Iodine, Manganese, Taurine, Alpha-Lipoic Acid, Vanadium, Vanadyl sulfate2024-11-29 10:47:42
Vitacost - Glonaturals Firming Eye Serum with Hyaluronic Acid, Alpha Lipoic Acid, DMAE & Vitamin C -- 1 fl ozVitacost - GlonaturalsBeauty & Personal Carecetearyl alcohol, cetyl palmitate, dimethylaminoethanol, glyceryl stearate, glycerin, dimethicone, alpha lipoic acid2024-11-29 10:47:42
Vitacost Alpha Lipoic Acid & Acetyl L-Carnitine HCl -- 240 CapsulesVitacost BrandVitamins & Supplementsmicrocrystalline cellulose, Alpha Lipoic Acid2024-11-29 10:47:42
Vitacost-Synergy 3000 Multivitamin -- 180 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, d-beta tocopherol, Biotin, Boron, calcium citrate, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Basic® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & Supplementsd-alpha tocopheryl succinate, Vitamin C, d-beta tocopherol, Biotin, dicalcium phosphate, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Mitochondrial Energy Booster† 15-Nutrient Blend -- 120 CapsulesVitacost-SynergyVitamins & SupplementsBenfotiamine, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, microcrystalline cellulose, D3, Niacin, Vitamin B6, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost-Synergy Once Daily® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Biotin, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Super Milk Thistle Complex - Advanced Formula -- 60 CapsulesVitacost-SynergyActive Lifestyle & FitnessN-Acetyl-L-Cysteine, Vitamin C, Vitamin A, Alpha Lipoic Acid2024-11-29 10:47:42
Vitacost-Synergy Twice Daily Energy† Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Benfotiamine, Biotin, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Manganese, Vitamin K2, Menaquinone-7, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Viteyes Classic Advanced Areds 2 Based Formula -- 60 CapsulesViteyesVitamins & SupplementsVitamin C, Vitamin E, Vitamin E, microcrystalline cellulose, Selenium, Alpha-Lipoic Acid2024-11-29 10:47:42
Viteyes Complete Eye & Total Body Health Multivitamin -- 180 CapsulesViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Biotin, Boron, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Viteyes Optic Nerve Support -- 90 TabletsViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Dicalcium phosphate, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Quercetin Dihydrate, stearic acid, Taurine, Alpha-Lipoic Acid, Vitamin B122024-11-29 10:47:42

Roles (2)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dithiolanes
heterocyclic fatty acidAny fatty acid containing a ring composed of atoms including at least one heteroatom.
thia fatty acidAny fatty acid having at least one of the chain methylene groups replaced by sulfur. Members of this group are believed to have important pharmacological (antioxidant and antiatherosclerosis) properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.76290.003245.467312,589.2998AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.21750.004023.8416100.0000AID485290; AID489007
Chain A, Beta-lactamaseEscherichia coli K-12Potency32.98380.044717.8581100.0000AID485294; AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency2.81840.125919.1169125.8920AID2549
acetylcholinesteraseHomo sapiens (human)Potency79.57580.002541.796015,848.9004AID1347397
RAR-related orphan receptor gammaMus musculus (house mouse)Potency56.21850.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency24.22030.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency24.22030.173734.304761.8120AID1346859
AR proteinHomo sapiens (human)Potency16.24770.000221.22318,912.5098AID1259247; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency36.46940.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency1.99530.000817.505159.3239AID588544
pregnane X nuclear receptorHomo sapiens (human)Potency19.31150.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.32800.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency1.00000.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency37.02160.001024.504861.6448AID588534; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency70.79460.001019.414170.9645AID588537
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.77830.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency25.11890.016525.307841.3999AID602332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency26.75760.057821.109761.2679AID1159526; AID1159528
Bloom syndrome protein isoform 1Homo sapiens (human)Potency14.12540.540617.639296.1227AID2528
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency14.09890.010039.53711,122.0200AID1469; AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
DNA polymerase betaHomo sapiens (human)Potency1.12200.022421.010289.1251AID485314
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency44.47620.000627.21521,122.0200AID651741; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.78280.00798.23321,122.0200AID2546
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency3.16230.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency0.16360.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency47.91330.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency3.16230.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency13.67150.002319.595674.0614AID651631
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency0.50120.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.50120.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency0.50120.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency0.50120.01418.602439.8107AID2572
Nuclear receptor ROR-gammaHomo sapiens (human)Potency66.82420.026622.448266.8242AID651802
TAR DNA-binding protein 43Homo sapiens (human)Potency0.89131.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.47750.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin-like modifier activating enzyme 2Homo sapiens (human)IC50 (µMol)2.68000.620016.325590.4600AID2006; AID2018
SUMO1 activating enzyme subunit 1Homo sapiens (human)IC50 (µMol)2.68000.620016.325590.4600AID2006; AID2018
hexokinaseTrypanosoma brucei brucei TREU927IC50 (µMol)0.20080.20084.602422.3780AID1632
SUMO-conjugating enzyme UBC9Homo sapiens (human)IC50 (µMol)2.68000.620016.325590.4600AID2006; AID2018
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)16.56001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)16.56001.150012.620025.6529AID855
VifHuman immunodeficiency virus 1IC50 (µMol)7.67000.270034.0015100.0000AID1117319
TatHuman immunodeficiency virus 1IC50 (µMol)5.89100.996039.8009100.0000AID1117361
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)7.67000.270026.3638100.0000AID1117319
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferaseMycobacterium tuberculosis H37RvIC50 (µMol)3.91003.910083.9944180.9200AID1376
CholinesteraseHomo sapiens (human)IC50 (µMol)1,000.00000.00001.559910.0000AID1796463
Aldo-keto reductase family 1 member B1Homo sapiens (human)Ki25.50000.01903.41939.3000AID1797503
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)1,000.00000.00000.933210.0000AID1796463
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (187)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1567489Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID1853364Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 0.1 to 100 uM incubated for 24 hrs by MTT assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853367Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 50 uM incubated for 24 hrs by LDH release assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1822759Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) at 50 uM incubated for 3 mins in presence of NADH by spectrophotometric analysis relative to control2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1377271Drug degradation in phosphate buffer assessed as H2S release by measuring test compound half life at 40 uM measured every 5 mins in presence of L-cysteine by UV-Vis spectrometry2017European journal of medicinal chemistry, Sep-29, Volume: 138Syntheses, toxicities and anti-inflammation of H
AID1377272Drug degradation in phosphate buffer assessed as H2S release by measuring H2S Cmax at 40 uM measured every 5 mins in presence of L-cysteine by UV-Vis spectrometry2017European journal of medicinal chemistry, Sep-29, Volume: 138Syntheses, toxicities and anti-inflammation of H
AID1853372Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as increase of TAC level at 50 uM by ABTS assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853377Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as inhibition of apoptosis at 50 uM incubated for 24 hrs by Hoechst 33258 staining fluorescence microscopy2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853375Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as protection against amyloid beta (1 to 42)-induced nuclear integrity damage at 50 uM incubated for 24 hrs by Hoechst 33258 staining2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853363Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 25 uM incubated for 24 hrs by MTT assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1567485Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID1525836Analgesic activity in CD1 albino mouse model of oxaliplatin-induced neuropathy hypersensitivity assessed as increase pain threshold at 40 mg/kg, po dosed from day 14 post oxaliplatin challenge and measured up to 90 mins post dose by cold plate test2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-
AID1853376Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as inhibition of apoptosis at 25 uM incubated for 24 hrs by Hoechst 33258 staining fluorescence microscopy2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853371Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease of TOS level at 25 uM2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1567487Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID1853370Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as increase of TAC level at 25 uM by ABTS assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853381Induction of DNA damage in human blood assessed as increase in 8-OH-dG level at 0.1 to 100 uM incubated for 24 hrs2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853369Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease in AChE activity at 50 uM incubated for 24 hrs by Colorimetric assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1567486Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID1853366Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 25 uM incubated for 24 hrs by LDH release assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853361Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 50 uM incubated for 24 hrs by MTT assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853365Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 100 uM incubated for 24 hrs by MTT assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853379Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as reduction in necrosis rate incubated for 24 hrs by Annexin V-FITC/propidium iodide staining flow cytometry2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853368Neuroprotective activity against amyloid beta (1 to 42)-induced neurotoxicity in human SH-SY5Y cells assessed as increase in cell viability at 100 uM incubated for 24 hrs by LDH release assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853380Genotoxicity in human blood assessed as frequency of sister chromatid exchange at 0.1 to 100 uM by BrdU/Giemsa staining based fluorescence assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1567484Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID1853374Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as protection against amyloid beta (1 to 42)-induced nuclear integrity damage at 25 uM incubated for 24 hrs by Hoechst 33258 staining2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1525835Analgesic activity in CD1 albino mouse model of oxaliplatin-induced neuropathy hypersensitivity assessed as increase pain threshold at 4 mg/kg, po dosed from day 14 post oxaliplatin challenge and measured up to 90 mins post dose by cold plate test2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-
AID1853378Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as reduction in necrosis rate at 25 to 50 uM incubated for 24 hrs by Annexin V-FITC/propidium iodide staining flow cytometry2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853362Neuroprotective activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease in AChE activity at 25 uM incubated for 24 hrs by Colorimetric assay2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1853373Antioxidant activity against amyloid beta (1 to 42)-induced Alzheimer's disease model in human SH-SY5Y cells assessed as decrease of TOS level at 50 uM2021RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11
Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.
AID1567488Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1796463Enzyme Inhibition Assay from Article 10.1021/jm049112h: \\Rational approach to discover multipotent anti-Alzheimer drugs.\\2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Rational approach to discover multipotent anti-Alzheimer drugs.
AID1797503Enzyme Inhibition Assay from Article 10.1016/j.bioorg.2006.09.004: \\Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.\\2006Bioorganic chemistry, Dec, Volume: 34, Issue:6
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,373)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990845 (19.32)18.7374
1990's416 (9.51)18.2507
2000's1028 (23.51)29.6817
2010's1571 (35.92)24.3611
2020's513 (11.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.33 (24.57)
Research Supply Index8.51 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index119.15 (26.88)
Search Engine Supply Index2.11 (0.95)

This Compound (63.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials322 (6.96%)5.53%
Reviews330 (7.13%)6.00%
Case Studies68 (1.47%)4.05%
Observational11 (0.24%)0.25%
Other3,897 (84.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (140)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease [NCT00090402]Phase 1/Phase 239 participants (Actual)Interventional2004-04-30Completed
The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion [NCT01056497]Phase 415 participants (Anticipated)Interventional2010-02-28Completed
Role of Alpha-Lipoic Acid Against Chemotherapy Induced Toxicities in Breast Cancer Patients [NCT03908528]64 participants (Actual)Interventional2019-03-01Completed
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status [NCT01835041]Phase 121 participants (Actual)Interventional2013-04-30Completed
Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study [NCT01294176]Phase 131 participants (Actual)Interventional2011-01-31Completed
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) [NCT01381354]Phase 138 participants (Actual)Interventional2010-10-31Completed
OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis [NCT05211622]Phase 480 participants (Anticipated)Interventional2022-03-10Not yet recruiting
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma [NCT02168140]Phase 116 participants (Actual)Interventional2014-09-30Completed
Effectiveness of Alpha Lipoic Acid on Clinical and Electrophysiological Recovery in Patients With Carpal Tunnel Syndrome Surgical Release [NCT02382328]Phase 240 participants (Actual)Interventional2016-02-29Completed
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers [NCT05733000]Phase 294 participants (Anticipated)Interventional2023-03-08Recruiting
The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study [NCT02056366]Phase 491 participants (Actual)Interventional2010-01-31Completed
Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population: A Randomized Controlled Trial [NCT04064814]Phase 460 participants (Actual)Interventional2019-09-14Completed
A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy [NCT03914404]Phase 4100 participants (Actual)Interventional2016-01-26Completed
The Association Between Oxidative Stress and Carbohydrate Metabolism Disorders in G6PD Deficient Individuals [NCT05571748]40 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Lipoic Acid for the Treatment of Progressive Multiple Sclerosis [NCT03161028]Phase 2115 participants (Actual)Interventional2018-07-01Active, not recruiting
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [NCT02168907]Phase 11 participants (Actual)Interventional2014-12-31Terminated(stopped due to Slow Accruals)
A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients [NCT02472626]Phase 1/Phase 20 participants (Actual)Interventional2015-12-31Withdrawn(stopped due to Drug Supply Issues)
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy [NCT05369793]Phase 360 participants (Actual)Interventional2022-08-01Completed
A Pilot Study of Antioxidant Therapy (Alpha Lipoic Acid, ALA) in OSA Patients [NCT05009901]Phase 2/Phase 380 participants (Anticipated)Interventional2022-06-01Recruiting
Role of Alpha Lipoic Acid Combined With Pulsed Radiofrequency in Treatment of Chronic Lumbosacral Radicular Pain: Prospective, Randomized Study [NCT03428139]Phase 2120 participants (Actual)Interventional2013-08-20Completed
Impact of Alpha-Lipoic Acid Ingestion on Glucose Tolerance in Subjects With Pre-Diabetes [NCT03612037]12 participants (Actual)Interventional2016-09-01Completed
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02484391]Phase 250 participants (Anticipated)Interventional2015-09-30Completed
Effect of Alpha-lipoic Acid on Inflammatory and Cardiac Fibrosis Markers in Diabetic Patients With Ischemic Cardiomyopathy [NCT06056687]60 participants (Anticipated)Interventional2023-03-01Recruiting
Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity [NCT01138774]103 participants (Actual)Interventional2010-01-31Completed
Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial. [NCT01221350]55 participants (Actual)Interventional2010-11-30Completed
A Protective Role of Alpha Lipoic Acid Against Possible Cardiovascular Events in Patients With Haemodialysis [NCT03912727]36 participants (Actual)Interventional2019-04-11Completed
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy [NCT01224353]Phase 2/Phase 3200 participants (Anticipated)Interventional2010-11-30Not yet recruiting
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia [NCT01355952]17 participants (Actual)Interventional2011-05-31Completed
Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy [NCT01313117]Phase 1/Phase 29 participants (Actual)Interventional2012-02-29Completed
[NCT02016495]Phase 40 participants InterventionalCompleted
The Role of the Glucosamine Pathway and Reactive Oxygen Species in the Pathogenesis of Diabetic Complications [NCT00703989]21 participants (Actual)Interventional2005-02-28Completed
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients [NCT02232152]Phase 119 participants (Actual)Interventional2015-01-06Completed
Combined Treatment of Angiotensin Receptor Blocker and Antioxidant Supplementation as a Novel Adjunctive Therapy for 24-hour Blood Pressure Improvement in Obstructive Sleep Apnea [NCT04021550]Early Phase 10 participants (Actual)Interventional2023-05-31Withdrawn(stopped due to Covid-19 Pandemic prevented this study from beginning)
Assessment of Resveratrol, Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy: A Randomized Control Trial [NCT06131918]Phase 2100 participants (Actual)Interventional2023-01-09Active, not recruiting
Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients Wit [NCT02613572]Phase 1/Phase 268 participants (Actual)Interventional2015-11-30Completed
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 [NCT05371288]Early Phase 150 participants (Anticipated)Interventional2024-06-30Not yet recruiting
A Randomized Controlled Study Using Alpha Lipoic Acid and CoQ-10 to Determine if Vestibular Function Can be Improved or Maintained Over the Course of One Year [NCT05945160]Early Phase 10 participants (Actual)Interventional2024-01-31Withdrawn(stopped due to Funding was terminated, the study will not enroll any subjects)
Effect of Systemic Administration of ALA (Alpha Lipoic Acid) as an Adjunct to Scaling and Rootplaning on Serum Resistin Levels in Patients With Chronic Periodontitis and Type 2 Diabetes Mellitus [NCT02775266]40 participants (Actual)Interventional2016-02-29Completed
The Role of R-alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease [NCT00764270]Phase 2/Phase 350 participants (Anticipated)Interventional2011-08-31Active, not recruiting
Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome [NCT02651636]40 participants (Actual)Interventional2014-06-30Completed
Impact of Lipoic Acid Use on Stroke Outcome After Reperfusion Therapy in Patients With Diabetes [NCT04041167]Phase 3120 participants (Anticipated)Interventional2018-08-01Recruiting
A 22-week Randomized, Cross-over Study Comparing the Effects of Quinapril and Quinapril Plus Alpha-lipoic Acid (ALA) on Patients With Diabetes Mellitus and Hypertension [NCT00795262]23 participants (Actual)Interventional2008-07-31Completed
A Randomized, Open-label, Balanced, Two-treatment, Four-period, Two-sequence, Single Dose, Fully Replicate, Crossover, Oral Bioequivalence Study of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Llko Ilac San. Ve Tic. A.S., Turkey and Thioctacid (Alph [NCT04214665]Phase 128 participants (Actual)Interventional2014-12-30Completed
Efficacy of the Association of Hyaluronic Acid With High Molecular Weight, α-lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D, in the Prevention of Spontaneous Abortion in Patients at Risk [NCT05449171]100 participants (Anticipated)Interventional2022-09-01Recruiting
The Effect of Alpha-Lipoic Acid on the Clinical Outcome of Patients With Sepsis [NCT05808946]Phase 2/Phase 360 participants (Anticipated)Interventional2023-03-10Recruiting
A Phase 1/2,Open-Label Study to Evaluate the Safety and Efficacy of the International Brain Research Foundation (IBRF) Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Patients With Severe Disorders of Consciousness [NCT02696512]Phase 1/Phase 230 participants (Anticipated)Interventional2016-03-31Recruiting
The Role of R-alpha Lipoic Acid in Prevention of Atherosclerotic Vascular Disease [NCT00765310]Phase 2/Phase 3100 participants (Anticipated)Interventional2009-04-30Active, not recruiting
Lipoic Acid for Neuroprotection in Secondary Progressive MS [NCT01188811]Phase 2/Phase 354 participants (Actual)Interventional2010-10-31Completed
Evaluation of the Effect of Pentoxifylline and α-Lipoic Acid as Adjunctive Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT05231980]Phase 2120 participants (Actual)Interventional2022-06-05Completed
Effect of Low Childhood Socioeconomic Status (SES) on Adult Endothelial Function and Nitric Oxide Bioavailability in Vivo and ex Vivo [NCT02115724]74 participants (Actual)Interventional2014-04-30Active, not recruiting
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis) [NCT01406704]Phase 426 participants (Actual)Interventional2004-01-31Terminated(stopped due to because of withdrawal of Avandia sale due to its risks outweigh its benefits)
Evaluation of The Effect of Alpha Lipoic Acid Administration on Oxidative Stress Markers and Occurrence of No-Reflow Phenomenon in Post Myocardial Infarction Patients [NCT05360602]60 participants (Anticipated)Interventional2022-07-01Not yet recruiting
Alpha Lipoic Acid to Decrease Treatment Related Pain and Side Effects During Concurrent Chemoradiation in HNSCC [NCT04042935]Phase 15 participants (Actual)Interventional2020-02-27Completed
Pilot Study: The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy [NCT01880372]1 participants (Actual)Interventional2013-09-30Terminated(stopped due to Low number of patients enrolled)
Evaluating the Effect of Alpha Lipoic Acid on Biochemical Markers, Length of Stay and Other Important Outcomes in Patients Admitted to Intensive Care Units. [NCT01888861]Phase 380 participants (Anticipated)Interventional2013-02-28Recruiting
A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC) [NCT01931787]Phase 115 participants (Actual)Interventional2013-10-31Completed
Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress [NCT00857376]Phase 277 participants (Actual)Interventional2008-03-31Completed
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial [NCT04475276]Phase 4120 participants (Anticipated)Interventional2021-02-23Recruiting
Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease [NCT01877590]Phase 466 participants (Actual)Interventional2013-11-30Completed
Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes [NCT01978405]Phase 4200 participants (Anticipated)Interventional2013-11-30Recruiting
The Effect of Lipoic Acid Natural Supplement on Cystine Stone Formation [NCT02910531]Phase 250 participants (Anticipated)Interventional2017-06-19Active, not recruiting
The Effects of Consumption of Vitamin E or Lipoic Acid on Serum Oxyphytosterol Concentrations in Subjects With Impaired Glucose Tolerance or Type II Diabetes [NCT01984567]20 participants (Actual)Interventional2013-04-30Active, not recruiting
Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy and Different Metabolic Parameters [NCT04322240]90 participants (Actual)Interventional2020-04-02Completed
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity [NCT05713799]Phase 260 participants (Anticipated)Interventional2024-01-03Not yet recruiting
Effect of Alpha Lipoic Acid on Obesity Related Comorbidities [NCT00994513]Phase 2/Phase 370 participants (Anticipated)Interventional2009-07-31Completed
Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning: A Randomized Clinical Trial [NCT02760823]Phase 250 participants (Anticipated)Interventional2016-05-31Not yet recruiting
Effects of 6 Months of Alpha-Lipoic Acid Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS [NCT02666170]40 participants (Anticipated)Interventional2016-01-31Not yet recruiting
Clinical Study Evaluating the Efficacy and Safety of Alpha-lipoic Acid in Patients With Ulcerative Colitis Treated With Mesalamine [NCT06067698]60 participants (Anticipated)Interventional2023-10-01Not yet recruiting
A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis [NCT00676156]Phase 140 participants (Actual)Interventional2005-12-31Completed
Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. [NCT01524861]Phase 490 participants (Actual)Interventional2011-12-31Completed
Alpha Lipoic Acid and Insulin Resistance [NCT00845156]68 participants (Actual)Interventional2008-01-31Completed
Vaginal Administration of Alpha Lipoic Acid vs Progesterone for the Subchorionic Hematoma Treatment [NCT02601898]Phase 454 participants (Actual)Interventional2015-01-31Completed
Assessment of Chronic Fatigue Syndrome as a Mitochondrial Disorder [NCT01872351]0 participants (Actual)Observational2011-11-30Withdrawn(stopped due to PI left the institution)
A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status [NCT01839981]Phase 110 participants (Actual)Interventional2013-07-31Completed
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial [NCT03788759]Phase 2/Phase 348 participants (Actual)Interventional2019-09-01Completed
[NCT00004770]1 participants Interventional1995-10-31Completed
A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E [NCT01495260]Phase 213 participants (Actual)Interventional2011-09-30Completed
Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis [NCT04518540]150 participants (Anticipated)Interventional2020-09-01Recruiting
Alpha Lipoic Acid and Polycystic Ovary Syndrome [NCT00505427]Phase 122 participants (Actual)Interventional2006-03-31Completed
Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise [NCT02937363]10 participants (Actual)Interventional2016-12-31Completed
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF [NCT02690064]13 participants (Actual)Interventional2015-04-30Active, not recruiting
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy [NCT01902381]Phase 212 participants (Actual)Interventional2013-08-31Terminated(stopped due to Drug sponsor suspended study prematurely then study was terminated. Expected enrollment was not met.)
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback [NCT02966665]Phase 1420 participants (Anticipated)Interventional2008-09-30Recruiting
Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia [NCT00002154]Phase 232 participants InterventionalCompleted
Comparison of G-Series Media System With Antioxidants Versus Standard G-Series Media System [NCT02999958]128 participants (Actual)Interventional2016-12-31Completed
Antioxidant Functions of Lipoic Acid [NCT00065624]Phase 216 participants Interventional2003-11-30Completed
Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT) [NCT00308971]Phase 262 participants (Actual)Interventional2006-03-31Completed
Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes [NCT00490867]Phase 230 participants (Actual)Interventional2004-07-31Completed
The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. [NCT01895621]Phase 464 participants (Actual)Interventional2013-03-31Completed
[NCT03023514]Phase 4172 participants (Actual)Interventional2015-03-31Completed
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis [NCT00997438]Phase 169 participants (Actual)Interventional2010-08-31Completed
Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers [NCT03062163]66 participants (Actual)Interventional2017-01-23Completed
Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial [NCT00112996]Phase 3244 participants (Actual)Interventional2007-01-31Completed
Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease [NCT00117403]Phase 175 participants (Anticipated)Interventional2006-01-31Completed
Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study [NCT01515839]100 participants (Actual)Interventional2009-05-31Completed
Natural Antioxidants in the Treatment of Multiple Sclerosis [NCT00010842]Phase 1/Phase 20 participants Interventional1999-09-30Completed
Painful HIV Neuropathy: Treatment With Alpha-Lipoic Acid [NCT00079807]Phase 1/Phase 260 participants Interventional2003-09-30Completed
Adding Antioxidants Into Human Embryo Culture Media [NCT02971878]128 participants (Actual)Interventional2016-11-30Completed
Immune Restoration by Lipoic Acid in AIDS [NCT00033176]Phase 233 participants Interventional2002-02-28Completed
The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes [NCT00398892]Phase 218 participants (Anticipated)Interventional2009-12-31Recruiting
Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus [NCT00187564]40 participants Interventional2004-08-31Completed
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease [NCT02774226]Phase 215 participants (Actual)Interventional2015-09-30Completed
Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake [NCT01396733]Phase 20 participants (Actual)Interventional2011-04-30Withdrawn
Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid [NCT00477607]Phase 2/Phase 339 participants (Actual)Interventional2007-10-31Completed
Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis [NCT01650181]Phase 450 participants (Actual)Interventional2011-11-30Completed
The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients [NCT05023863]Phase 2/Phase 370 participants (Anticipated)Interventional2021-09-01Not yet recruiting
"Changes in Appetite, Weight, Body Composition, Endothelial Function and Biomarkers in Patients With the Cardiometabolic Syndrome: Comparison of a Combination of Berberine, Lipoic Acid, and Picrorhiza (CAR-191) Versus Placebo (The BANGALORE Study)" [NCT01696448]28 participants (Actual)Interventional2012-08-31Completed
Effect of Alpha-Lipoic Acid Supplementation on the Incidence of Postoperative Atrial Fibrillation in Cardiac Surgery Patients [NCT06151652]Phase 4350 participants (Anticipated)Interventional2023-12-01Not yet recruiting
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leu [NCT01768897]Phase 167 participants (Actual)Interventional2013-01-31Completed
A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers [NCT01808300]Phase 142 participants (Actual)Interventional2013-02-28Completed
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers [NCT01766219]Phase 1/Phase 217 participants (Actual)Interventional2013-05-31Completed
A Novel Role of Alpha Lipoic Acid in Comparison With Selenium in Mitochondrial Resuscitation and miRNA-126 Expression in Hemodialysis Patients Randomized, Prospective, Controlled Study [NCT05266794]Phase 468 participants (Actual)Interventional2019-01-22Completed
Evaluation of the Effect of Different Treatments on Pain Scores and Self-reported Oral Health-related Quality of Life in Individuals With Burning Mouth Syndrome: a Randomized Controlled Clinical Trial [NCT06040190]Phase 4150 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease [NCT01058941]Phase 1/Phase 267 participants (Actual)Interventional2010-09-30Completed
Oxidative Stress Links Aging, Activity and Mobility Limitation [NCT01177189]87 participants (Actual)Interventional2011-07-01Terminated(stopped due to Inadequate effect size.)
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma [NCT05325281]Phase 124 participants (Anticipated)Interventional2022-10-31Recruiting
CVD Risk and Prevention in Early Glucose Intolerance [NCT00122447]84 participants (Actual)Interventional2005-05-31Completed
Effect of Alpha-lipoic Acid Supplementation on Regression of Low-grade Squamous Intraepithelial Lesions (LSIL)-Double Blind, Randomized, Placebo-controlled Trial [NCT05485259]100 participants (Actual)Interventional2020-01-15Completed
The Possible Role of Alpha-Lipoic Acid in Improving Endothelial Dysfunction and Atherosclerosis in Children With Type 1 Diabetes Mellitus [NCT05679037]Phase 352 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study [NCT00962429]Phase 27 participants (Actual)Interventional2009-02-28Completed
An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers [NCT01537549]Phase 1/Phase 211 participants (Actual)Interventional2010-09-14Completed
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups [NCT00328601]Phase 3170 participants Interventional2005-02-28Completed
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups [NCT00977483]Phase 3460 participants (Actual)Interventional1998-05-31Completed
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Refractory Diabetic Peripheral Neuropathy [NCT05507697]Phase 1/Phase 242 participants (Anticipated)Interventional2022-05-19Recruiting
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)? [NCT02348125]Phase 150 participants (Anticipated)Interventional2016-03-31Recruiting
Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading [NCT02439879]Phase 445 participants (Actual)Interventional2009-12-31Completed
Assessment of the Effect of Alpha Lipoic Acid Supplementation on Inflammatory Factors, Insulin Resistance, Glycemic Control and Anthropometric Indices in Patients With Metabolic Syndrome [NCT03589690]44 participants (Anticipated)Interventional2018-07-25Not yet recruiting
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study [NCT00237718]Phase 2385 participants (Actual)Interventional2006-04-30Completed
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease [NCT01054768]Phase 237 participants (Actual)Interventional2009-08-31Completed
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study [NCT04436419]40 participants (Actual)Interventional2018-07-02Completed
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment [NCT04881851]90 participants (Anticipated)Interventional2015-05-07Recruiting
Efficacy and Safety of Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy: a Randomized, Parallel, Open-label, Multicenter, Phase IV Clinical Trial (OPTIMUM Trial) [NCT04846673]Phase 4150 participants (Anticipated)Interventional2021-05-14Recruiting
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis [NCT02133664]Phase 1/Phase 254 participants (Actual)Interventional2014-06-30Completed
Assessing The Effect of Alpha Lipoic Acid on Uterine Scar Healing After Cesarean Section by Using Saline Contrast Sonohysterography [NCT03257514]Phase 2102 participants (Actual)Interventional2017-06-01Completed
Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention [NCT01780974]Phase 1/Phase 242 participants (Actual)Interventional2013-04-30Completed
Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial [NCT03493841]Phase 120 participants (Actual)Interventional2018-06-08Completed
Clinical Study of Lipoic Acid on Ischemic Heart Failure [NCT03491969]Phase 4300 participants (Anticipated)Interventional2018-05-01Not yet recruiting
A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer [NCT03370159]Phase 1/Phase 20 participants (Actual)Interventional2018-06-30Withdrawn(stopped due to Sponsor decided not to move forward)
Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males [NCT03342599]16 participants (Actual)Interventional2013-10-31Completed
A Multicenter, Interventional, Two-arm, Parallel-group, Randomized, Double-blinded, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Symptomatic Diabetic Polyneuropathy in Egypt [NCT05813496]Phase 4400 participants (Anticipated)Interventional2022-10-26Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00090402 (3) [back to overview]Change in Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) Scores From Baseline to 12 Months
NCT00090402 (3) [back to overview]Change in Mini-Mental State Exam (MMSE) Score From Baseline to 12 Months
NCT00090402 (3) [back to overview]F2-isoprostane Level Urine F2-Isoprostanes
NCT00122447 (2) [back to overview]AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level
NCT00122447 (2) [back to overview]AIM 1: Change in Flow Mediated Dilation (FMD) (%)
NCT00237718 (2) [back to overview]Interleukin-6 (IL-6)
NCT00237718 (2) [back to overview]F2-isoprostane (F2-iso)
NCT00477607 (3) [back to overview]Total Amount of Prescribed Cisplatin Dose Administered
NCT00477607 (3) [back to overview]Ototoxicity Measurement
NCT00477607 (3) [back to overview]Malondialdehyde (MDA) Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]RANTES Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]RANTES Levels
NCT00997438 (10) [back to overview]cAMP Levels
NCT00997438 (10) [back to overview]Lipoic Acid Levels
NCT00997438 (10) [back to overview]cAMP Levels
NCT01054768 (1) [back to overview]C-Reactive Protein
NCT01058941 (2) [back to overview]Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months
NCT01058941 (2) [back to overview]Change From Baseline in Activities of Daily Living (ADL) at 18 Months
NCT01177189 (3) [back to overview]Exercise-induced Oxidative Stress (i.e. Free Radical Concentrations and Levels of Lipid Peroxidation)
NCT01177189 (3) [back to overview]Vascular Function (i.e. % Flow Mediated Vasodilation)
NCT01177189 (3) [back to overview]Vascular Function Following the Antioxidant Intervention
NCT01188811 (3) [back to overview]Disability Measures: Mobility
NCT01188811 (3) [back to overview]Safety Measure: Adverse Events
NCT01188811 (3) [back to overview]Brain Atrophy by MRI
NCT01221350 (18) [back to overview]Induced Sputum Carbonylated Proteins at Baseline
NCT01221350 (18) [back to overview]Induced Sputum Carbonylated Proteins at Endpoint
NCT01221350 (18) [back to overview]Induced Sputum Eosinophils at Baseline
NCT01221350 (18) [back to overview]Induced Sputum Eosinophils at Endpoint
NCT01221350 (18) [back to overview]Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint
NCT01221350 (18) [back to overview]Spirometric FVC Values at Endpoint
NCT01221350 (18) [back to overview]Spirometric FVC Values at Baseline
NCT01221350 (18) [back to overview]Spirometric FEV1 Values at Endpoint
NCT01221350 (18) [back to overview]Spirometric FEV1 Values at Baseline
NCT01221350 (18) [back to overview]Spirometric FEF Values at Endpoint
NCT01221350 (18) [back to overview]Spirometric FEF Values at Baseline
NCT01221350 (18) [back to overview]Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint
NCT01221350 (18) [back to overview]Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline
NCT01221350 (18) [back to overview]Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline
NCT01221350 (18) [back to overview]Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint
NCT01221350 (18) [back to overview]Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline
NCT01221350 (18) [back to overview]Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline
NCT01221350 (18) [back to overview]Inflammatory IL-4 Sputum Levels at Endpoint
NCT01313117 (3) [back to overview]Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile
NCT01313117 (3) [back to overview]Cumulative Rate of Adverse Events
NCT01313117 (3) [back to overview]Proportion of Patients Who Complete the Proposed Regimen of Daily ALA
NCT01537549 (2) [back to overview]Adverse Events
NCT01537549 (2) [back to overview]Cerebral Oxidative Stress Markers
NCT01766219 (4) [back to overview]Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria
NCT01766219 (4) [back to overview]Progression-free Survival
NCT01766219 (4) [back to overview]Response Rate Defined as Proportion of Patients With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
NCT01766219 (4) [back to overview]Overall Survival
NCT01780974 (2) [back to overview]White Matter Hyperintensity Volume (Brain MRI)
NCT01780974 (2) [back to overview]Trails Making Test Part B (Executive Function)
NCT02133664 (4) [back to overview]California Verbal Learning Test-II (CVLT-II)
NCT02133664 (4) [back to overview]Controlled Oral Word Association Test (COWAT)
NCT02133664 (4) [back to overview]Paced Auditory Serial Addition Task (PASAT)
NCT02133664 (4) [back to overview]Stroop Color-Word Test
NCT02439879 (1) [back to overview]Total Symptoms Score
NCT02613572 (6) [back to overview]Phase II: Mean Annual Change in Best-Corrected Visual Acuity (BCVA)
NCT02613572 (6) [back to overview]Phase I: Percentage of Participants With Adverse Events
NCT02613572 (6) [back to overview]Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Total Area of Geographic Atrophy (mm2) - Unadjusted
NCT02613572 (6) [back to overview]Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Square Root of Area of GA (mm) - Unadjusted
NCT02613572 (6) [back to overview]Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Total Area of GA (mm2) - Adjusted
NCT02613572 (6) [back to overview]Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Square Root of Area of GA (mm) - Adjusted
NCT02774226 (4) [back to overview]Change in Flow Mediated Dilation
NCT02774226 (4) [back to overview]Change in PWV (Pulse Wave Velocity)
NCT02774226 (4) [back to overview]FEV1 %Predicted
NCT02774226 (4) [back to overview]Percent of ACH to Heat Max

Change in Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) Scores From Baseline to 12 Months

The Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL) measures an individual's ability to carry out tasks that are important for daily living and capture functional changes. Scores for each question range from 0 (no assistance needed) to 2 (full assistance needed), and were assessed by informant interview. The combination of scores for ADL (ranging from 0-18) and IADL (0-14) is the outcome (0-32), with higher scores indicating lesser ability to carry out daily living tasks. (NCT00090402)
Timeframe: baseline, 12 months

Interventionunits on a scale (Mean)
Placebo4.2
Fish Oil0.7
Fish Oil and Lipoic Acid0.9

[back to top]

Change in Mini-Mental State Exam (MMSE) Score From Baseline to 12 Months

The MMSE is a measure of global cognitive function, and scores range from 0-30, with a lower score indicates greater cognitive impairment. (NCT00090402)
Timeframe: baseline, 12 months

Interventionunits on a scale (Mean)
Placebo-4.64
Fish Oil-4.27
Fish Oil Plus Lipoic Acid-1.00

[back to top]

F2-isoprostane Level Urine F2-Isoprostanes

F2-isoprostane is a biomarker was used as an effective indicator for detecting a decrease in systemic oxidative damage (oxidative damage in lipids). Urine F2-Isoprostanes were used to avoid ex vivo lipid peroxidation that can occur with plasma samples. (NCT00090402)
Timeframe: baseline, 12 months

Interventionnanogram per miligram (Mean)
Placebo0.40
Fish Oil-2.02
Fish Oil Plus Lipoic Acid0.45

[back to top]

AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level

Inflammatory marker (NCT00122447)
Timeframe: 12 months of intervention

Interventionmg/L (Mean)
Aspirin (ASA) 325 mg PO Once Daily-1.27
Olmesartan (ARB) 40 mg PO Once Daily-2.34
Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily0.23
Placebo0.32

[back to top]

AIM 1: Change in Flow Mediated Dilation (FMD) (%)

Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression (NCT00122447)
Timeframe: 12 months of intervention

Interventionpercentage of arterial dilation change (Mean)
Aspirin (ASA) 325 mg PO Once Daily-0.0012
Olmesartan (ARB) 40 mg PO Once Daily0.018
Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily0.014
Placebo0.0053

[back to top]

Interleukin-6 (IL-6)

IL-6 is a sensitive laboratory assay for serum levels of interleukin-6, which is a pro-inflammatory cytokine used to evaluate the inflammatory response. (NCT00237718)
Timeframe: month 6

Interventionpg/ml (Mean)
ALA and Vitamin E19
Placebo20

[back to top]

F2-isoprostane (F2-iso)

F2-iso is a sensitive laboratory assay for serum levels of F2-isoprostane, which is a biomarker of oxidative stress. (NCT00237718)
Timeframe: month 6

Interventionng/ml (Mean)
ALA and Vitamin E0.077
Placebo0.073

[back to top]

Total Amount of Prescribed Cisplatin Dose Administered

Maximum cumulative dose of cisplatin (mg/m^2) administered during the course of chemotherapy. (NCT00477607)
Timeframe: cisplatin treatment period between 10 weeks and up to 16 weeks.

Interventionmg/m^2 (Mean)
Arm 1239.7
Arm 2191.5

[back to top]

Ototoxicity Measurement

"Any American Speech and Hearing Association (ASHA)-significant hearing loss in the Sensitive Region for Ototoxicity frequencies between baseline measurement and any follow-up measurement.~ASHA criteria are defined as~20 decibel (dB) increase at any test frequency,~10 dB increase at any two consecutive test frequencies, or loss of response where there was previously a response at any three test frequencies." (NCT00477607)
Timeframe: Baseline measurement occurred prior to first cisplatin treatment session. Follow-up measurements occurred up to 3 months after last cisplatin treatment.

Interventionparticipants (Number)
Arm 17
Arm 27

[back to top]

Malondialdehyde (MDA) Levels

Computed maximum increase relative to baseline for each subject = (max MDA during treatment) - baseline MDA level. (NCT00477607)
Timeframe: Baseline measurement occurred prior to first cisplatin treatment session. Follow-up measurements occurred up to 3 months after last cisplatin treatment.

InterventionuM=micro-moles/liter (Mean)
Arm 10.27
Arm 20.47

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 24 hour

Interventionng/mL (Mean)
MS - Secondary Progressive0.78
MS - Relapsing Remmitting0.87
Healthy Controls0.78

[back to top]

RANTES Levels

(NCT00997438)
Timeframe: 24 hour

Interventionpg/mL (Mean)
MS - Secondary Progressive47184.9
MS - Relapsing Remitting36281.4
Healthy Controls76751.7

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 48 hour

Interventionng/mL (Mean)
MS - Secondary Progressive0.55
MS - Relapsing Remmitting0.7
Healthy Controls0.57

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 4 hours

Interventionng/mL (Mean)
MS - Secondary Progressive268.6
MS - Relapsing Remmitting252.75
Healthy Controls394.1

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 1 hour

Interventionng/mL (Mean)
MS - Secondary Progressive1376.14
MS - Relapsing Remmitting1609.07
Healthy Controls1428.05

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 2 hours

Interventionng/mL (Mean)
MS - Secondary Progressive1125.71
MS - Relapsing Remmitting1167.33
Healthy Controls1348

[back to top]

RANTES Levels

(NCT00997438)
Timeframe: 48 hour

Interventionpg/mL (Mean)
MS - Secondary Progressive44905.8
MS - Relapsing Remmitting42593.8
Healthy Controls60578.5

[back to top]

cAMP Levels

(NCT00997438)
Timeframe: 4 hours

Interventionpmol cAMP/mg protein (Median)
MS - Secondary Progressive72.6
MS - Relapsing Remmitting79.1
Healthy Controls103.5

[back to top]

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 3 hours

Interventionng/mL (Mean)
MS - Secondary Progressive667.86
MS - Relapsing Remmitting638.4
Healthy Controls793.89

[back to top]

cAMP Levels

(NCT00997438)
Timeframe: 2 hours

Interventionpmol cAMP/mg protein (Median)
MS - Secondary Progressive75.9
MS - Relapsing Remmitting75.8
Healthy Controls96.6

[back to top]

C-Reactive Protein

C-Reactive Protein (CRP) was measured by a clinical laboratory. Measuring the quantity of serum CRP is helpful in recognizing inflammatory states. (NCT01054768)
Timeframe: 6 months

Interventionmg/l (Mean)
Alpha-lipoic Acid and Acetyl-L-carnitine11.4
Placebo6.8

[back to top]

Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months

The ADAS-cog assesses general cognitive function over multiple domains and evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates greater impairment on a range of scores from 0 to 70. A total score of 70 indicates maximum severity. (NCT01058941)
Timeframe: Baseline and 18 months

Interventionunits on a scale (Mean)
Lipoic Acid and Omega-3 Fatty Acids6.61
Placebo3.40

[back to top]

Change From Baseline in Activities of Daily Living (ADL) at 18 Months

The Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) is used to assess activities of daily living in people with AD using a structured interview to ask the AD participant's caregiver/study partner to assess functional ability over a wide range of performance measures. A higher ADL score indicates greater impairment in functional ability; scores range from 0 to 27. (NCT01058941)
Timeframe: Baseline and 18 months

Interventionunits on a scale (Mean)
Lipoic Acid and Omega-3 Fatty Acids-11.58
Placebo-13.45

[back to top]

Exercise-induced Oxidative Stress (i.e. Free Radical Concentrations and Levels of Lipid Peroxidation)

"Free radicals and levels of lipid peroxidation were measured using electron paramagnetic spectroscopy and ELISA assays.~A minimum value is 0 and a maximum value is 10. A higher value is a worse outcome." (NCT01177189)
Timeframe: 8 weeks

Interventionunits on a scale (Mean)
Arm 11.51
Arm 22.7

[back to top]

Vascular Function (i.e. % Flow Mediated Vasodilation)

The effect on flow mediated vasodilation is measured using Doppler ultrasound. (NCT01177189)
Timeframe: 8 weeks

Interventionpercentage of vasodilation (Mean)
Arm 17.4
Arm 25.2

[back to top]

Vascular Function Following the Antioxidant Intervention

The degree of vasodilation following the antioxidant intervention measured by Doppler ultrasound. (NCT01177189)
Timeframe: 8 weeks

Interventionpercentage of vasodilation (Mean)
Arm 15.8
Arm 28.2

[back to top]

Disability Measures: Mobility

(NCT01188811)
Timeframe: Change in Timed 25 Foot Walk from baseline to year 2

Interventionseconds (Mean)
Lipoic Acid-1.0
Placebo0.1

[back to top]

Safety Measure: Adverse Events

(NCT01188811)
Timeframe: adverse events recorded from baseline to year 2

,
Interventionoccurences (Number)
Total number adverse eventsTotal number serious adverse events
Lipoic Acid819
Placebo696

[back to top]

Brain Atrophy by MRI

(NCT01188811)
Timeframe: % change brain volume from baseline to year 2

Interventionwhole brain percent volume change (Mean)
Lipoic Acid-0.4
Placebo-1.3

[back to top]

Induced Sputum Carbonylated Proteins at Baseline

Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products (NCT01221350)
Timeframe: Baseline

Interventionnmol/mg (Mean)
Lipoic Acid7.5
Placebo10.12

[back to top]

Induced Sputum Carbonylated Proteins at Endpoint

Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. (NCT01221350)
Timeframe: 60 days

Interventionnmol/mg (Mean)
Lipoic Acid3.24
Placebo4.21

[back to top]

Induced Sputum Eosinophils at Baseline

Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: Baseline

InterventionEosinophil percentage in sputum cells (Mean)
Lipoic Acid12.88
Placebo6.10

[back to top]

Induced Sputum Eosinophils at Endpoint

Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. (NCT01221350)
Timeframe: 60 days

InterventionEosinophil percentage in sputum cells (Mean)
Lipoic Acid6.39
Placebo5.68

[back to top]

Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint

Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: 60 days

Interventionratio (Mean)
Lipoic Acid58.6
Placebo37.5

[back to top]

Spirometric FVC Values at Endpoint

Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: 60 days

InterventionLiters (Mean)
Lipoic Acid2.82
Placebo3.06

[back to top]

Spirometric FVC Values at Baseline

Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. (NCT01221350)
Timeframe: Baseline

InterventionLiters (Mean)
Lipoic Acid2.74
Placebo3.07

[back to top]

Spirometric FEV1 Values at Endpoint

Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: 60 days

InterventionLiters (Mean)
Lipoic Acid2.26
Placebo2.35

[back to top]

Spirometric FEV1 Values at Baseline

Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. (NCT01221350)
Timeframe: Baseline

InterventionLiters (Mean)
Lipoic Acid2.01
Placebo2.37

[back to top]

Spirometric FEF Values at Endpoint

Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: 60 days

InterventionLiters/sec (Mean)
Lipoic Acid5.47
Placebo6.10

[back to top]

Spirometric FEF Values at Baseline

Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. (NCT01221350)
Timeframe: Baseline

InterventionLiters/sec (Mean)
Lipoic Acid4.89
Placebo6.09

[back to top]

Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint

"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: 60 days

Interventionunits on a scale (Mean)
Lipoic Acid5.57
Placebo5.10

[back to top]

Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline

"The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.~There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html)." (NCT01221350)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Lipoic Acid3.86
Placebo3.72

[back to top]

Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline

Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. (NCT01221350)
Timeframe: Baseline

Interventionratio (Mean)
Lipoic Acid81.42
Placebo35.77

[back to top]

Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint

Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: 60 days

Interventionunits on a scale (Mean)
Lipoic Acid19.13
Placebo17.71

[back to top]

Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline

Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). (NCT01221350)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Lipoic Acid13.65
Placebo14.46

[back to top]

Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline

Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: Baseline

Interventionpg/mL (Mean)
Lipoic Acid37.77
Placebo39.90

[back to top]

Inflammatory IL-4 Sputum Levels at Endpoint

Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. (NCT01221350)
Timeframe: 60 days

Interventionpg/mL (Mean)
Lipoic Acid14.53
Placebo23.19

[back to top]

Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile

Based on acceptable adverse event (AE) profile and continual reassessment method dose escalation. (NCT01313117)
Timeframe: 4 months

Interventionmg (Number)
Alpha Lipoic Acid500

[back to top]

Cumulative Rate of Adverse Events

(NCT01313117)
Timeframe: 4 months

Interventionparticipants (Number)
Alpha Lipoic Acid9

[back to top]

Proportion of Patients Who Complete the Proposed Regimen of Daily ALA

(NCT01313117)
Timeframe: 4 months

Interventionparticipants (Number)
Alpha Lipoic Acid7

[back to top]

Adverse Events

Incidence and severity of adverse events (NCT01537549)
Timeframe: at 25 weeks

InterventionNumber of Adverse Events (Number)
Juvenon23

[back to top]

Cerebral Oxidative Stress Markers

changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy (NCT01537549)
Timeframe: at baseline and at week 5

InterventionRatio (Mean)
Juvenon at Baseline4
Juvenon at 1 Month4.6

[back to top]

Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria

Adverse events will be captured using the National Cancer Institute Common Terminology Criteria (NCI CTCAE) version 3.0 (NCT01766219)
Timeframe: Up to 1 month completion of study treatment, assessed up to 1 year

InterventionParticipants (Count of Participants)
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 2,300 mg/m²4
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 1,200/3,000 mg/m²2
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 600/3,000 mg/m²11

[back to top]

Progression-free Survival

Estimated using Kaplan-Meier techniques as well as RECIST 1.1. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). (NCT01766219)
Timeframe: From the first dose of 6,8-bis(benzylthio)octanoic acid to disease progression (DP) or death due to any cause, assessed up to 4 years

Interventionmonths (Median)
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 2,300 mg/m²1.6
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 1,200/3,000 mg/m²0
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 600/3,000 mg/m²2.5

[back to top]

Response Rate Defined as Proportion of Patients With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

Using the RECIST version 1.1 as defined by patient with 95% confidence interval will be included. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study (NCT01766219)
Timeframe: From the start of the treatment until disease progression, assessed up to 4 year

,,
Interventionparticipants (Number)
Stable DiseaseProgressionNot Evaluable
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 1,200/3,000 mg/m²200
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 2,300 mg/m²040
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 600/3,000 mg/m²272

[back to top]

Overall Survival

Estimated using Kaplan-Meier techniques. (NCT01766219)
Timeframe: From the first dose of 6,8-bis(benzylthio)octanoic acid to death, assessed up to 4 years

Interventionmonths (Median)
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 2,300 mg/m²4.7
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 1,200/3,000 mg/m²1.6
Treatment (6,8-bis[Benzylthio]Octanoic Acid) 600/3,000 mg/m²3.94

[back to top]

White Matter Hyperintensity Volume (Brain MRI)

(NCT01780974)
Timeframe: Baseline and 12 months

,
Interventioncubic centimeters (Mean)
Baseline12 Months
Lipoic Acid Plus Omega-3 Fatty Acids5.315.07
Placebo6.135.14

[back to top]

Trails Making Test Part B (Executive Function)

"The trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient as he or she connects the trail. If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment." (NCT01780974)
Timeframe: Baseline, 6 months, and 12 months

,
Interventiontime to completion (seconds) (Mean)
Baseline6 Months12 Months
Lipoic Acid Plus Omega-3 Fatty Acids81.5969.2571.10
Placebo69.5762.5369.75

[back to top]

California Verbal Learning Test-II (CVLT-II)

"CVLT-II is a measure of verbal learning/memory. It is comprised of lists containing 16 words, each of which fit into one of four categories of shopping list items. Five trials are administered followed by presentation of a different list. Free and cued recall of the original list is assessed. The change in long delay free recall from baseline to 12 weeks will be the measurement used for outcome." (NCT02133664)
Timeframe: baseline to 12 weeks

Interventioncorrect responses (Mean)
Lipoic Acid and Omega-3 Fatty Acids1.57
Placebo1.65

[back to top]

Controlled Oral Word Association Test (COWAT)

The COWAT is a letter fluency test. Participants are asked to generate as many words as possible beginning with a particular letter of the alphabet during one minute. Alternate versions using 3 letters are used for each examination. The change in total number of words produced for the 3 letters from baseline to 12 weeks will be the outcome. (NCT02133664)
Timeframe: baseline to 12 weeks

Interventionwords (Mean)
Lipoic Acid and Omega-3 Fatty Acids0.70
Placebo0.39

[back to top]

Paced Auditory Serial Addition Task (PASAT)

The PASAT is a measure of working memory and sustained attention frequently used in multiple sclerosis treatment outcome studies. The examinee is presented with a series of numbers at 2 second intervals on an audiotape and responds by always adding the last two numbers on the tape before the next number is presented. The change in total number of correct responses from baseline to 12 weeks is the measurement for the outcome. (NCT02133664)
Timeframe: Baseline to 12 weeks

Interventioncorrect responses (Mean)
Lipoic Acid and Omega-3 Fatty Acids2.24
Placebo3.38

[back to top]

Stroop Color-Word Test

"The Stroop test assess attention and executive function.The task consists of 3 tasks with only red, green, and blue colors used. The first task asks the subject to name the colors of spots on cards. If a subject can perform this task the second task is performed in which a subject must read the names of colors listed on cards (which are printed in congruent colors). In the third task, the subject is shown a series of words naming colors but the words and colors are mismatched; so the word yellow may be red, the word blue may be green and so forth. The subject is instructed to ignore the word and name the color. The subject will have the tendency to read the word rather than name the color, the so-called Stroop effect. This third part of the test is referred to as the interference condition and is the critical measurement. The change in time it takes to complete the interference from baseline to 12 weeks is the outcome measure." (NCT02133664)
Timeframe: baseline to 12 weeks

Interventionseconds (Mean)
Lipoic Acid and Omega-3 Fatty Acids-5.59
Placebo-2.87

[back to top]

Total Symptoms Score

Total symptoms score is a summation of presence, severity, and duration of the four main positive neuropathic sensory symptoms: lancinating/stabbing pain, burning pain, paresthesia, and asleep numbness (NCT02439879)
Timeframe: 20 weeks

Interventionunits on a scale (Mean)
Alpha Lipoic Acid Treatment2.5
Alpha Lipoic Acid Withdrawal3.1

[back to top]

Phase II: Mean Annual Change in Best-Corrected Visual Acuity (BCVA)

Unit of Measure. Mean annual change in best-corrected visual acuity was calculated by taking the letter score at 18 months minus the baseline letter score. This value was then divided by 18 months and then multiplied by 12 months to get the mean annual change in visual acuity. Timepoints for the study were baseline, 0, 6, 12, and 18 months. The baseline and 18 month timepoints were used for the annualized calculations as noted below. (NCT02613572)
Timeframe: 18 months

Interventionletters/year (Mean)
Placebo 1200mg-3.8
Alpha Lipoic Acid (ALA) 1200mg-3.1

[back to top]

Phase I: Percentage of Participants With Adverse Events

The percent of adverse events that develop will be stratified by the alpha lipoic acid dose. (NCT02613572)
Timeframe: 15 days

InterventionParticipants (Count of Participants)
Alpha Lipoic Acid (ALA) 600 mg11
Alpha Lipoic Acid (ALA) 800 mg10
Alpha Lipoic Acid (ALA) 1200 mg10

[back to top]

Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Total Area of Geographic Atrophy (mm2) - Unadjusted

The rate of change over time in area of Geographic Atrophy (GA) in the study eye. This is determined by masked grading of Fundus Autofluorescence by an image reading center, in participants randomized to placebo or 1200 mg once daily of ALA. The values represent the annualized change from baseline to 18 months. Mean annual geographic atrophy growth rate was calculated by taking the total atrophy area at 18 months minus the baseline area. This value was then divided by 18 months and then multiplied by 12 months to get the annual growth rate. Timepoints for the study were baseline, 0, 6, 12, and 18 months. The baseline and 18 month timepoints were used for the annualized calculations as noted below. (NCT02613572)
Timeframe: 18 months

Interventionmm^2/year (Mean)
Placebo 1200mg1.21
Alpha Lipoic Acid (ALA) 1200mg1.71

[back to top]

Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Square Root of Area of GA (mm) - Unadjusted

The rate of change over time in area of Geographic Atrophy (GA) in the study eye. This is determined by masked grading of Fundus Autofluorescence (FAF) by an image reading center, in participants randomized to placebo or 1200 mg once daily of ALA. The values represent the annualized change from baseline to 18 months. Mean annual geographic atrophy growth rate was calculated by taking the total atrophy area at 18 months minus the baseline area. This value was then divided by 18 months and then multiplied by 12 months to get the annual growth rate. For square root transformed data, the square root of area was used. Timepoints for the study were baseline, 0, 6, 12, and 18 months. The baseline and 18 month timepoints were used for the annualized calculations as noted below. (NCT02613572)
Timeframe: 18 months

Interventionmm/year (Mean)
Placebo 1200mg0.28
Alpha Lipoic Acid (ALA) 1200mg0.31

[back to top]

Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Total Area of GA (mm2) - Adjusted

The rate of change over time in area of Geographic Atrophy (GA) in the study eye. This is determined by masked grading of Fundus Autofluorescence by an image reading center, in participants randomized to placebo or 1200 mg once daily of ALA. The values represent the annualized change from baseline to 18 months. Mean annual geographic atrophy growth rate was calculated by taking the total atrophy area at 18 months minus the baseline area. This value was then divided by 18 months and then multiplied by 12 months to get the annual growth rate. Timepoints for the study were baseline, 0, 6, 12, and 18 months. The baseline and 18 month timepoints were used for the annualized calculations as noted below. (NCT02613572)
Timeframe: 18 months

Interventionmm^2/year (Mean)
Placebo 1200mg1.29
Alpha Lipoic Acid (ALA) 1200mg1.63

[back to top]

Phase II: Mean Annual Growth of Geographic Atrophy (Fundus Autofluorescence) - Square Root of Area of GA (mm) - Adjusted

The rate of change over time in area of Geographic Atrophy (GA) in the study eye. This is determined by masked grading of Fundus Autofluorescence (FAF) by an image reading center, in participants randomized to placebo or 1200 mg once daily of ALA. The values represent the annualized change from baseline to 18 months. Mean annual geographic atrophy growth rate was calculated by taking the total atrophy area at 18 months minus the baseline area. This value was then divided by 18 months and then multiplied by 12 months to get the annual growth rate. For square root transformed data, the square root of area was used. Timepoints for the study were baseline, 0, 6, 12, and 18 months. The baseline and 18 month timepoints were used for the annualized calculations as noted below. (NCT02613572)
Timeframe: 18 months

Interventionmm/year (Mean)
Placebo 1200mg0.27
Alpha Lipoic Acid (ALA) 1200mg0.32

[back to top]

Change in Flow Mediated Dilation

Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and 12 weeks after treatment. (NCT02774226)
Timeframe: Change from Baseline and 12 weeks

Interventionpercentage of flow mediated dilation (Mean)
Tetrahydrobiopterin (BH4)0.26
Antioxidant Cocktail-1.5

[back to top]

Change in PWV (Pulse Wave Velocity)

Change in pulse wave velocity (carotid to femoral) as measured using tonometry with the Sphygmocor Xcel system at baseline and after 12 weeks of treatment. (NCT02774226)
Timeframe: Change from Baseline and 12 weeks

Interventionm/s (Mean)
Tetrahydrobiopterin (BH4)-0.36
Antioxidant Cocktail0.34

[back to top]

FEV1 %Predicted

Forced Expiratory Volume in 1 second. Pulmonary Function Test (PFT). (NCT02774226)
Timeframe: Change from Baseline and 12 weeks

Interventionpercentage of predicted (Mean)
Tetrahydrobiopterin (BH4)-3.6
Antioxidant Cocktail-4.2

[back to top]

Percent of ACH to Heat Max

The laser imaging camera is a special camera that shines a low energy laser light on the surface of the skin to measure blood flow. The FLPI makes graphs, photos, and movies of skin blood flow. Acetylcholine is a vasoactive substance that will be used to increase skin blood flow. This variable is the percent of dilation caused by acetylcholine out of the max dilation cause by the warm water bath (44 C). (NCT02774226)
Timeframe: Change from Baseline and 12 weeks

Interventionpercent (Mean)
Tetrahydrobiopterin (BH4)4.2
Antioxidant Cocktail-0.8

[back to top]